<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:linkedspls:uuid:657F04C4-DF90-4589-8E67-95EA5B343A04">
    <rdfs:label>Imatinib</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B7B24D6-F8B8-41EA-BC3D-19496AE00103">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F2B5431-3B47-492B-9021-134C0C0993C2">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3783BF66-40FD-4C55-B4D6-62A054C85BA8">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>CML and Ph+ ALL</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81F19A65-E4FC-4F8D-B79A-06D61BAA7316">
    <pav:lastSavedOn>2014-08-10 22:32:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6ACCDAF7-66DD-4016-AADA-48DE1CB7DFA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:046EE207-4499-4C25-8AE6-81689BAB026D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9E08AB9-C391-4B7F-9FD1-9B221053D7E3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-08-10 22:32:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9A32269-12E8-4F88-B586-093F86654667"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:416FC75E-6F07-42CC-A084-7EFDF0B22B6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:95F033BF-10B1-489F-B523-1E9063A71F38"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D093E80C-8C3F-4367-AB75-18154005898A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85364423-8E61-48AC-859C-BFD1E1B50F60">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23B5DEBF-032B-44AD-86B6-0A5665A87474">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E933301-5FE2-4827-85D6-3D71B5A93C82">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:E69D5D39-08C2-4F6A-82D2-9BB1F2BAE7B2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAEA2C0B-9BFC-4566-8723-27638A73064A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:83BEA37D-2B27-4864-B526-C93110E8DB8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:75F69FE6-25C0-4682-B792-5AD11062986C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1CD2473-CFAA-4FF5-809A-08E5500CC025"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3FAA571-7DA0-4F0F-8719-53D670425B4F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5A40A436-DB97-4F9D-A2CE-71234ECF455A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E54A8F3F-19BB-4FB2-8D79-2CEC0CD3C261"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE20F363-A208-47A4-89DD-9BA37E9DFC28"/>
    <pav:lastSavedOn>2014-08-09 20:21:01 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-09 20:11:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1302EB76-E1D9-4A85-B199-2A527967E8C1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D14C1107-3ED0-4351-923C-D114C4559F07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F23D9B73-FB11-4CF4-8608-428C04B0402E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8DD07D2-59CF-4D79-B610-9E30AFBB09EC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Grade 4 neutropenia, neutropenia </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4CA707A-F9EB-4AA9-B18A-66390BDE647D">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE05AC28-7AC6-4765-98AB-EFB89FE08808">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5443451A-1BD5-4BA4-AB88-460E06BDC51C">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E40CE4B-F0A4-4DD0-B730-62D6531EBDAF">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>BCR/ABL1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67D77FED-0781-4E61-8DBB-F4CB65833749">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB5FBDC0-F925-435E-8365-1ABE9E5C1500">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3FE67137-DFCA-4572-B7FC-D2EF3A58416B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DBD21EF-4879-4D35-803C-84ED3C4FEEDC"/>
    <pav:lastSavedOn>2014-08-10 21:44:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:08A2680D-3FFF-46DD-B0BF-1F3AC550FA86"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF8EE52-6654-4BF0-A83E-59D2212994C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8BF8D66-ED88-4471-A73B-229532B32886"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF47BD25-ABBC-45C5-816F-2E7FBC1E9E01"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-08-10 21:44:00 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D3D660C2-955B-4037-A95B-5711916747A8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:3B0D28B6-E566-40AF-B9F5-913B9629DE7F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F2E15C6-E95F-4A74-9F00-48CF06B103E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36DD3963-A8D6-4D07-AC3E-1DC7BD45A6C2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDF7BD4E-553F-4F43-9E6A-1BDDB1AE305A">
    <ao:body rdf:resource="urn:linkedspls:uuid:DB6B01C8-0B4A-4A1B-96FB-1F1C5B4D4BAB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:9D12DEFB-A7A6-432B-A02F-A226BC80460F</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 18:56:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFA9A1B1-F6CA-4A27-A169-261051BF3E8A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-06-01 18:44:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:241AC904-E593-4A48-9E32-7846142BF6D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55CB7EF8-A6B6-4D3F-9A7F-DCF6A7E08FE4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22783C7-ABFC-4DA3-8A47-F388EB9CA645"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:12247663-6D8E-4333-8FCA-0EC431436874"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3146B9AA-68A2-4E19-91D9-D0AC98F6AC7C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF247ADE-CEC1-4294-951B-E346EEFCF880">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>???</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BFBC3AC-D8B5-415E-AB79-C58932414E1C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:14A4B8C7-A2F8-4432-9D84-03A047BA880A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AED49CB9-4E63-4554-BD0A-FA513B375D56"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF508BF5-0707-4BB5-9669-06BE9AD4A04C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD29F999-6BE6-4296-85E2-66DAA123889B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549"/>
    <pav:createdOn>2014-06-01 20:20:14 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB28026C-C47A-45ED-AA26-E514F6865F6C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4999A1DA-C288-46D8-A62C-B991C9A4B2F7"/>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:777356F6-9617-4A7E-BF6D-EC58735B2B5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3BEDEE1-6E3A-44BE-B2E7-1831F2CE98A5">
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:08B0B51B-D5DC-40CD-B081-FA75E1BD984D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B477D910-8941-4126-90E7-507D5D492660</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B5E5DA48-A12E-45BE-B26B-291C933A1819"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5443451A-1BD5-4BA4-AB88-460E06BDC51C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0FA9FE6F-9E01-47C4-8CFE-9C9218690AF5"/>
    <pav:lastSavedOn>2014-06-23 11:57:50 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB87CE99-B099-4809-88F7-56477D6C0E03"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAA6B2E8-AB2E-48A6-9E3D-440B18DADA76"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA75E90E-DD48-4D34-BF92-E73CE9762328"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:36F5E628-9E69-4B85-BE35-CCE2A0B36037"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAD1465D-090B-448F-AD6B-DE55AC35DDE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F2B5431-3B47-492B-9021-134C0C0993C2"/>
    <pav:createdOn>2014-06-23 11:57:50 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C6C1DB3-50EA-4E8C-9744-0620557B06F4">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10E13CA8-AB04-4965-8986-0EA63CB5BCC5">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3A42395-76B8-4E33-A7D0-66177BD5A4B4">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-23 12:01:16 -0400</pav:createdOn>
    <ao:prefix>). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3A42395-76B8-4E33-A7D0-66177BD5A4B4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E3A42395-76B8-4E33-A7D0-66177BD5A4B4</domeo:uuid>
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAE5BAE6-F9FD-40B0-88DA-1DFD96F59585">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CF72A32-62A3-44B4-8085-2A3743064FB1">
    <pav:previousVersion>urn:domeoserver:annotationset:C4D6D414-7EDE-4B56-A45C-30F5A0023D11</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BC4D324-CC64-42F6-BE5A-6538E9028251"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F1A881E-327B-4A8F-842E-98D7A69CA8E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C49849A-1D00-4AB4-B40F-F15EBE87D0B0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-23 12:06:14 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-23 12:00:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8870565E-1A59-41E3-9AAE-8EE2DC9C2A90"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6159ACE8-3CEC-4C84-88D5-F682557F209F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5654E5A-29EC-44FE-85CA-DDC4C8E58B7D"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3A42395-76B8-4E33-A7D0-66177BD5A4B4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE66CAE4-E60C-4BCA-A279-D9DF438AEF11">
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA1A5436-6353-49E0-B158-D24D32105570"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:698DED5B-0966-49DB-A5A0-88E02DBD1E0B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:624952BE-02FA-4DBB-A8F8-7C324A7D27AE"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B30E27C7-9FC2-49F9-8322-0F737014ACC2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2014-06-02 11:43:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F9F0CCA-B6E8-41D6-84C8-186912D7E20B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB5A86FB-B345-4E1A-8900-8DEEEA090BF2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8A08744-2AEE-46C6-95C7-7CD50737E7F4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FAC7603-5023-4D0C-AB60-484403F16245">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8272D2B6-0C9A-4ABA-B13E-74867D45B903">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8C4E5F2-9109-4AC8-9FFD-1D78D4BE6D6B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A448D700-3F1E-4D64-870C-505840A1EC4E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B858186-07FF-44BE-863D-05D40DD39D4F"/>
    <pav:lastSavedOn>2014-06-02 11:23:49 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-02 11:20:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:1AC91D44-43AB-461A-BBAE-2DB0CE3D63A9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAF55A68-F83C-4EA3-ACCE-A7D22C0D74A8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F473F356-8095-46F4-93CD-1CF983427CE6">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:605401F9-CEC0-4386-9F96-10216E94DB09">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A5DB27A0-A0F6-4DAA-8AED-0377D85505FD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:22D1D12A-D376-4A58-BE50-04FA3F26EAA7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:146074E6-D887-4B6B-A91C-D2BF04FB29EE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94ADE34C-D689-4935-81C9-D5C7435911A2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E140DE6F-DDD3-4D85-86B9-5A73C2EEB94C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BA002F2-35EE-4CE2-BCB7-FE83BF8FF7A5"/>
    <pav:createdOn>2014-06-01 18:56:26 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7925A8BE-4401-4E13-A60C-0CFB0EFB7480"/>
    <pav:lastSavedOn>2014-06-01 18:56:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE4DF44-922B-4B4F-9E0E-28118340C6C7">
    <ao:body rdf:resource="urn:linkedspls:uuid:60B2FC2A-0FCD-47E1-8AF6-036903D2D8FE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:DF1D873F-A2EA-43B8-A80C-4117D7771126</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-06-01 21:01:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4FDB6D9-6003-4748-9F44-DAD96C90C75E"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:945AB3F9-D117-4A09-A4D4-85964D29ACAC"/>
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:724D3B35-67C5-43A4-BC96-46E359B92EE8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26FC75F4-DD53-4BA3-BAE1-B9F1BF18603C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E118AF70-C2CB-42BF-9C66-805D9273A823"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1056089-0FB5-44D2-A976-B96EE2910380"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFC5FB64-7D92-4E3C-9B93-7194C4840DCB">
    <ao:suffix> </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-08-10 23:53:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFC5FB64-7D92-4E3C-9B93-7194C4840DCB"/>
    <domeo:uuid>EFC5FB64-7D92-4E3C-9B93-7194C4840DCB</domeo:uuid>
    <ao:exact>Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, significantly increased ivacaftor exposure [measured as area under the curve (AUC)] by 8.5-fold. Based on simulations of these results, a reduction of the KALYDECO dose to 150 mg twice a week is recommended for co-administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin.\nCo-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold. Therefore, a reduction of the KALYDECO dose to 150 mg once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.\nCo-administration of KALYDECO with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of ivacaftor. Therefore, food containing grapefruit or Seville oranges should be avoided during treatment with KALYDECO</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:254E53F4-ADF4-4713-938E-1C0386D7A5E0">
    <ao:prefix>) and long duration of warfarin therapy. </ao:prefix>
    <domeo:uuid>254E53F4-ADF4-4713-938E-1C0386D7A5E0</domeo:uuid>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses </ao:exact>
    <pav:createdOn>2014-06-23 12:05:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(see CLINICAL PHARMACOLOGY:</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:254E53F4-ADF4-4713-938E-1C0386D7A5E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:261DB21A-00ED-42B3-A086-14062057B96A">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDEC54E1-AF7F-4766-992E-F0C0D8B346C1">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490">
    <ao:prefix>Table 4 describes the characteristics of the breast cancers in the NSABP P-1 trial and includes tumor size, nodal status, ER status. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors</ao:exact>
    <pav:createdOn>2014-06-01 20:46:16 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1E2C8EC-EDF4-4FC4-B7CC-24E7ED0C5310">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72BD3694-98FC-40F3-B2A3-1555044DD90D">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:203316B7-C346-4B4D-B8A9-98258A6F0717">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0770A34-42E4-4D3B-8AED-154FDB4FDE79">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <pav:createdOn>2014-08-09 21:09:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:77FB8661-A2DD-439B-B8DD-146100034BF9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:60AD1445-5032-42EF-9218-A28C9C349C0A</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E19C86C-AF8F-4049-B770-4A8BB73E1C87"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECB8B4B2-C490-4136-AE0D-92FF68DEDD4B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1784625-BB2F-4C6B-8074-9FE645D297D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA0E4629-4676-4414-9CCE-D47355EFE0B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55224E52-1CF2-4A49-B39E-56ECA1F81AAD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:156F9063-0388-4A4D-8A0C-941D0AA70CD2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-09 21:51:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:298DF7AB-668F-4166-8E6F-F84060B77787"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C2FB89B-001A-4C72-9EA0-3B9B45E12DA7">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-02 11:54:54 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA139D1F-5943-42B5-B46F-936534FF180D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8613DBE-E23B-4505-97DC-D1A8904A9B30"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E40CE4B-F0A4-4DD0-B730-62D6531EBDAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52659CB2-2836-4827-AA04-68D75C4A4B31"/>
    <pav:lineageUri>urn:domeoserver:annotation:21EBE267-EA4C-4E5B-852A-115A464D4531</pav:lineageUri>
    <pav:createdOn>2014-06-02 11:54:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AA7F636-6F42-4B80-841F-F2B140D5A4DA"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E80F8715-EB61-449E-A924-4D82E72F059E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E099BC1-7905-4F64-8057-156FC53ADB58"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26FC75F4-DD53-4BA3-BAE1-B9F1BF18603C">
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7BBECA1-0C77-4D3E-89CF-EBB73FABD318">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49ACD5A8-48E7-4C4E-A4B9-DAF372EB24DC">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E80AFBE-0A52-4745-AE9E-9AB372773FFD">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21BD891C-1A7D-4254-B84D-F08896010FBE">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3BEFDA7-8A18-494B-B506-AA2F2DD504AD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:181A738E-65CA-4CF8-837C-CF3C74EFD546">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B0EBE3D-E880-49F6-AED2-BCC056A7B6BA">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34076-0) INFORMATION FOR PATIENTS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34076-0) INFORMATION FOR PATIENTS</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB39EC49-39E7-4F01-BDFA-DBB2A633035D">
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B4EC10A-9E0A-4112-8F47-278513A77774">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED21B315-38D0-4925-8381-807711159BD6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB740418-B021-4E92-901A-49B4D3119A5D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2C813541-EF8D-439B-BD7D-0C5BC606AD32</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6281053-9FBB-4089-87CE-BFFA4C1A86FA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4EB1751-EA99-44EF-AF37-8F62006DC59D"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B2E425D-1901-4350-941B-9E3FF9C34BF9"/>
    <pav:lastSavedOn>2014-08-10 22:45:03 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F912A186-EFE8-4683-829C-7D3591BC246E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <pav:createdOn>2014-08-10 22:44:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D111BF54-7F6A-4982-BA99-8FBD11522EEE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>836CABF8-8E8E-4739-8AF2-34CCA31278ED</domeo:uuid>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <pav:createdOn>2014-06-01 20:28:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D224A37-870B-4566-9300-3CA34F697E87">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DB028A4-A674-45A7-9DF4-00F4939D4E28"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:31F532E4-DE6A-4195-8A66-D15780958299"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A18250EA-6D04-4F8A-9913-544C0BDC8A33"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F691598D-0180-4ECA-93E6-DAA5BF3618E6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:99474912-AAF4-4456-AA66-26B7DD743B6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:49C91135-7B0C-49C9-B2B9-940C06C1D40B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:203316B7-C346-4B4D-B8A9-98258A6F0717"/>
    <pav:createdOn>2014-08-10 23:44:54 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6D4A6F1-109F-462F-9CA4-78E8572F04D5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:EE01FD67-F11F-4A6E-B7D1-86831A95B2F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F8B5277-C411-4FE5-998F-6BE4513B3692"/>
    <pav:lastSavedOn>2014-08-10 23:44:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC735722-FA0F-47F5-A97D-9F2FE406D9C2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78BB6A54-2C48-44AF-BC4F-5130336B0B4A">
    <ao:body rdf:resource="urn:linkedspls:uuid:D0F83D6C-DD82-4333-BFF3-DE92D85685DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DBC567B-06FC-4E32-AF97-1F12BA46DF14"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4FF148F-DA8E-460A-9416-12EABD3C0787"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:77FA206B-E97B-4DB2-95C8-2CAEE18D73ED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-06-01 18:43:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A76CAD7-6AFA-4C1E-AFDD-B56F1FA2AD22"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DD28267-65FB-4736-98AA-42F22B2AF105"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:createdOn>2014-06-01 18:43:11 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0672652F-D2D6-4850-B292-41777DDD93A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD417187-DEC1-41B4-8747-B7CCC73A8AD1">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:270E4F6D-B8A5-47C4-AC1E-6B8F995D7933">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
    <rdfs:label>BCR/ABL1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC963D6E-86F0-41A8-BBB4-F5713CDAB9AE">
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <pav:lastSavedOn>2014-08-09 20:47:21 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:304BC021-E734-4EB0-BB31-8EC9289EEA29"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:FD2460AE-F6A8-455E-BE21-2CC0ED140BBF</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3F354912-5F3D-49DA-AAB4-6F25C6574A88"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <pav:createdOn>2014-08-09 20:47:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FC340C7-3054-4024-A6D3-03D1C8C19F0C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5A65BEB-DCCF-48F2-BE58-B211F9B5FBB1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EF6BFC4-564D-45AE-A0FD-E209B90914B7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFF8F6B3-CBEA-41C1-8B89-E750F37D5BF0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Capecitabine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B">
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:640C2180-199F-4CE7-9036-107C9B01972B"/>
    <domeo:uuid>640C2180-199F-4CE7-9036-107C9B01972B</domeo:uuid>
    <pav:createdOn>2014-06-02 11:43:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AED49CB9-4E63-4554-BD0A-FA513B375D56">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4">
    <ao:exact>Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-01 20:37:15 -0400</pav:createdOn>
    <domeo:uuid>26386F6E-0E97-4ACB-AFBA-2C331A2E54E4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>endent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B77785EF-DE8D-41E0-B5D0-E667FBF3B656">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD5AFBC9-5CBF-4536-B0E9-B65EF81A8338"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07F88819-D6E2-461A-A044-5E3CEC9E1E63"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:90C7CDC4-7785-42F1-95CA-9FC7A3CD3BFC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3B18E66-3D1C-4FC4-9C87-0991DA7E46F7"/>
    <pav:lastSavedOn>2014-06-23 12:13:38 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F7C77E5-CD77-4EEB-B9A7-819B66A75D1A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBB3AC8A-6B1E-443C-9E5A-F8E3DBAD2600"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:15B7AF82-B5F2-4FF0-9558-6A06D36E22B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4941BF92-9F56-48D7-8134-30C1DC2D4B83"/>
    <pav:createdOn>2014-06-23 12:13:39 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:48FC149D-D717-4D19-AD79-8509F49B64C3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:097C6676-BD3C-476D-AEF9-38CD5B1039FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B4C100B-79CD-44F8-9EBE-37292F3907B3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FDE2809-7490-4004-8ECD-428B36F48B79">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3FAA571-7DA0-4F0F-8719-53D670425B4F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F3FAA571-7DA0-4F0F-8719-53D670425B4F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-09 20:20:33 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3FAA571-7DA0-4F0F-8719-53D670425B4F"/>
    <ao:exact>In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin [see Clinical Pharmacology (12.3)]. The maximum observed INR value increased by 91%. This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites.</ao:exact>
    <ao:prefix>. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA. These events occurred in patients with and without liver metastases. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF9E7431-69B5-4BAE-A020-9DB51109BA3A">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECF411C7-5E58-4EB7-ABF0-33EEE5C22D04"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:A2165F85-DA12-4AC2-A372-6EBD213B5987</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-02 11:30:34 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:21BD891C-1A7D-4254-B84D-F08896010FBE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:056DFCFD-7A3D-456D-BD1C-B5E0D7699D95"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:72BD3694-98FC-40F3-B2A3-1555044DD90D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AB6F307-87A7-4718-8807-327A89AC39E4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E495D799-FBD4-414C-B469-19EB5A801B2C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8650AFA8-B61A-4A92-A987-B371590DFBCE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B82BB5C-552F-4359-8117-65E2C21FB4AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6734B02-ECA2-4C72-BF40-9F8C068486B0"/>
    <pav:lastSavedOn>2014-06-02 11:34:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>E84A315B-C921-4512-B11A-846BE09D8237</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-02 11:38:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:066D80FC-F8B2-4D72-8338-3DC5AD62AE34">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00321</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Amitriptyline</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-01 20:28:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D"/>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <domeo:uuid>1461839B-2331-4FA6-B624-FD2100276C0D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1407863-3005-4220-AB14-446C3EC7B195">
    <pav:createdOn>2014-06-01 20:37:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:5B38A180-D6D0-4D80-BB8F-BE5F1F6BC3D0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:24EFE4BC-3895-4D41-9ACB-83753AC5B633"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FCC9F3C-187A-4D10-B907-FACC9E668E85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:06682B01-A432-4E05-8191-6DAD4683C330"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:26386F6E-0E97-4ACB-AFBA-2C331A2E54E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AA8627E-CA88-4386-8040-4A006B86F19F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ADC2C0BA-8531-4C8E-9016-F3E0BD15B5E3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:854159CB-9EDA-4075-8EA9-8582AC113366"/>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:59D463C5-ED0D-4FAD-8454-93F2D804878B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D220057A-D861-4B4F-9869-A27D03B3B259">
    <ao:body rdf:resource="urn:linkedspls:uuid:F4CA707A-F9EB-4AA9-B18A-66390BDE647D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E73C31F-DD90-40FB-A350-824AB17D8D15"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A347C07-F901-4339-8495-C605FC5F87B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DA58976-B060-4F74-BC58-B197894534CD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C819792D-415B-45BE-A528-AFC18D3037EA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:lastSavedOn>2014-08-10 22:05:10 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A57D9DD7-B213-4EFD-8323-63FD88F88EBC"/>
    <pav:createdOn>2014-08-10 22:05:06 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4340CA7-5C58-47D6-B8CD-28A2E3CB9F9F"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:5A03DEF5-DCED-47AB-8D84-AAA5E3B44D01</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E5DA6FF-D900-4436-B714-1C6B44F671AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.1alpha</foafx:version>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:homepage></foafx:homepage>
    <foafx:build>050</foafx:build>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE7E5906-C054-4CC5-AFBC-4C80B78D5D6E">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9079CD80-B336-4A30-A2A1-47B7530408B0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9079CD80-B336-4A30-A2A1-47B7530408B0"/>
    <pav:createdOn>2014-08-09 12:40:47 -0400</pav:createdOn>
    <ao:exact>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary). </ao:prefix>
    <domeo:uuid>9079CD80-B336-4A30-A2A1-47B7530408B0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49E4005A-EE50-404F-A52D-3249F8464394">
    <ao:body rdf:resource="urn:linkedspls:uuid:A9B2E784-E7B7-4BE7-9644-C8BAC52301DD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BED2D48F-56C7-41B5-8920-32197D90ECAF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1913406-D5F7-4C32-A307-A55268FB07FA"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA5CB1FD-D1F7-4527-A5EC-8F6AD26EDF25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6207BDE-B892-441F-BE0A-0D7E3B0CC6B7"/>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-02 11:44:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA8988F3-1346-4B78-A914-D18381CEF56A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:270E4F6D-B8A5-47C4-AC1E-6B8F995D7933"/>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:62F162C4-135E-4C80-90D5-5AE8570228F2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82A863E2-4600-4792-BDAB-897D7BCBB8A7">
    <rdfs:label>Not change necessary</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#no-change-necessary</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N20b1b98dfab14c858348ad226f68d39a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A479CBD-F4BF-4914-A061-B99A738ED0ED">
    <domeo:uuid>6A479CBD-F4BF-4914-A061-B99A738ED0ED</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-10 23:13:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A479CBD-F4BF-4914-A061-B99A738ED0ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF953C5-E175-48F1-A277-32D8647EE8BB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41E9C212-448C-48B6-B598-B84492BE6DF6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:475179DB-17CE-4C9C-B063-3C6AB85F1E4B">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-metabolizer</poc:Variant>
    <rdfs:label>intermediate-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62809121-0387-4AED-BAB6-89A4ABBCA85C">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8C4E5F2-9109-4AC8-9FFD-1D78D4BE6D6B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24EFE4BC-3895-4D41-9ACB-83753AC5B633">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2A29FDE-1792-4A92-88A1-2A747318521F">
    <ao:body rdf:resource="urn:linkedspls:uuid:A10D537E-04E7-41F2-9631-AEDCE1B74585"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61365053-2F51-497B-9187-D1A7F6A291ED"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DBDA217-1594-4A26-BB47-582F603B9509"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:97894498-771C-4274-B512-B487D71522F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-06-23 12:11:13 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE74ECF6-B96D-4299-9C46-7591BA467AB4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CC1A70D-952A-454E-BAF0-4254B50EEE9F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF878A63-A581-4A98-90E1-091C1136F553"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A4B363B-C27F-4AB6-B71E-79BCC511008A"/>
    <pav:lastSavedOn>2014-06-23 12:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC41527C-085A-4940-B990-08A2D0350C2C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DA13589C-1D72-4EA6-845E-1F31F387919B</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <pav:createdOn>2014-06-02 11:40:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9"/>
    <domeo:uuid>62C44EE7-9565-49BB-8348-F00484C13CA9</domeo:uuid>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961ABB97-90DE-483F-87EA-8A701EE196B4">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9256A7ED-564A-4D27-85A7-9C2759B66DD0">
    <ao:context rdf:resource="urn:domeoclient:uuid:96F6E308-9D41-4BFF-942D-A5CC552467C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9ABCB3C0-F126-474E-8961-241E8212DB5F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F95282A-14FE-42FB-87B5-900AA0BBA0FA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <pav:createdOn>2014-06-23 12:01:01 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD241C8A-F9B8-4F6B-A5B8-FCE8ADC1A98D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-23 12:01:00 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E8D4706-2C30-430D-876C-02FC03E707F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:939532D8-0588-46A2-9E45-D593E1510B49"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2BF3473-D005-42A0-BEE4-6A0A276400D1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:87E5E1B1-AEEA-4028-84DE-F008E501A291</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:911C0C58-84E4-4EEF-87E7-47D9336DB7DF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB129B84-A824-4B8C-BF70-9759A68C71B0">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:298DF7AB-668F-4166-8E6F-F84060B77787">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:614FD391-7B36-429E-BE37-CC28603291F6">
    <pav:createdOn>2014-08-09 20:50:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:641CB75A-B08D-4C90-8629-2BABDCC233BE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B3931F7-E70A-466D-8C09-934673F99DDA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <pav:lastSavedOn>2014-08-09 20:50:23 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A8F5C12-2D71-4D44-8E06-0292198A80FE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7C6F945-F6AB-415D-815F-D36B9BEA98A3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:90D9A756-BB32-44FF-A32B-723CE7EA83C4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:BC65C579-A4E3-44E7-ADBC-3FBF5089378F</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C">
    <pav:createdOn>2014-06-01 20:31:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C8277B5-2CEA-46C3-AB1E-07D587682276">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4941BF92-9F56-48D7-8134-30C1DC2D4B83">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB147F25-1B88-4069-9256-A953968F81BF">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A36D52A9-2A1C-46F3-92DD-39141B9A088A">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>desirable =/= recommended </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:310FFE09-A6AC-4320-ABE2-C36D42DFD8E9">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>UGT1A1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC8FB036-D968-47D5-9988-95AB8EF17F4A">
    <poc:MedicalCondition>clotting factor synthesis</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A358766-A107-42A5-BE6E-8F31F1BA691B">
    <pav:createdOn>2014-06-01 19:36:29 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6B815268-BD7A-4C42-94FB-72A1EC3BBF19"/>
    <pav:lastSavedOn>2014-06-01 19:37:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D993426A-9987-4FDD-A8FC-A9C8758BECBE</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <permissions:permissions rdf:nodeID="N9a260759f1024a099ae0060cb5ce17d8"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:346C6C85-1835-4795-8A9D-306529D3828A">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BD38BB9-E595-46B7-AFF3-42EC7BDCBC08">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:888B1342-C453-47DA-B417-3463BE7491AD"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB66CB97-AE1B-44B7-9572-EEEE1FB82DB9"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD701664-00FA-430B-8ED4-68328F2A3736"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0483221-F475-4081-ADBF-98A1997B6D25"/>
    <pav:previousVersion>urn:domeoserver:annotationset:23454B4F-40CB-4632-A856-37BD98252499</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-10 22:10:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7958A3F8-2010-4802-8B0D-1AEC97EE0741"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:529A0D57-6754-4EFB-BE67-B5338A1E859F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F473F356-8095-46F4-93CD-1CF983427CE6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5A01BA3-C965-4226-BB21-CD71F0AF3F8A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:lastSavedOn>2014-08-10 22:10:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38B239A4-676D-417F-8FF3-8EFD527E04C9">
    <domeo:uuid>38B239A4-676D-417F-8FF3-8EFD527E04C9</domeo:uuid>
    <ao:exact>Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. Therefore, co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St. John's Wort) is not recommended</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38B239A4-676D-417F-8FF3-8EFD527E04C9"/>
    <pav:createdOn>2014-08-10 23:22:19 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> [</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47F5DF8D-6E93-4BEA-B0A0-65FBF75E4A01">
    <ao:body rdf:resource="urn:linkedspls:uuid:994E0CF7-0D24-46F2-9307-D7615779EC81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AFD6F26E-7280-4ECC-9675-EB5879DA5B53"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9388AA14-511A-422D-96D9-2C12EAEAF089</pav:previousVersion>
    <pav:lastSavedOn>2014-06-02 11:38:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-02 11:38:36 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD16BE80-5B8E-43B8-B9F5-17051DEF6533"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F5428A8-04B1-4598-99C2-43DB74E0B647"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF4B710F-A32F-47E2-BECB-106A837F1F66"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:546478F7-7C88-4C9A-B137-679B6C0B0C4A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2ED739B4-0C5F-4523-B4E9-9392184D80A5"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E84A315B-C921-4512-B11A-846BE09D8237"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:79A7B917-A122-4B38-B666-8BFEE9FD1385"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:715FBAF4-B02C-4176-9F1B-0A9DD25FB455"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08A53415-7699-4FDC-BDCA-84A6BB818418">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:95883503-619E-47C5-A2AA-69C742D7C90B"/>
    <pav:createdOn>2014-08-10 21:33:41 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-08-10 21:33:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB72EBD3-8FAF-4CC6-AD82-74EE55FB1C67"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7D91160-12DF-4885-A5EB-9FF75CE648B9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F212693A-E0F3-4F5D-81E2-7422222513C4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C9982E0-656A-4CE6-91BD-09368A1A1F57"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACED33D5-A0D0-4B2F-90C6-8FC7E39EED97"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E380C046-2990-425C-A6EE-5AB34E5B492A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5738AE20-15FF-4DBA-87E3-67FAB9159316"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4B2801D-AD10-4FC0-A504-C6F5EBC7F83E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15CAD71A-E73D-41C4-A612-FD85495EA125"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A57D9DD7-B213-4EFD-8323-63FD88F88EBC">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF894966-52DA-4712-A6F7-2E418E0E66C6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B7DC40D-1B3D-4BA0-BA38-41B9DA65EEF3">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:075A7CA2-6401-4610-A335-F1E2AE43B9E0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4308DA5-4474-492B-AFCD-CFEE3F159D1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C3AC9B3-D601-4136-A811-7C38BDF19C43"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:781BBA63-F58B-4E56-AD8A-0062F37377E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E7CA85B-4A8F-4CBE-8231-92F268786E9F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D93C557-7BA6-4DCF-B075-71C884D5D59F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB320B68-62FC-4457-B449-7E0CD9890D51"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-01 20:31:15 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6AF5971-80AE-4A6C-A511-F82D7494B773"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7DD5680-2391-4EC5-A99C-AC221DB7CF67">
    <ao:body rdf:resource="urn:linkedspls:uuid:523071B4-7A9B-4843-94CE-574131C7DAB0"/>
    <pav:createdOn>2014-06-01 20:46:16 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7762E8FF-2F66-49F9-8F33-6361BE15F2B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A26E190-386D-487C-9204-1A9FF093B3BF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:275605A0-79AB-4D06-9E3C-B817A21D1490"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EA68AC5-1674-484B-B8D0-2AECA70B9FE8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4693793C-A4BA-4B78-8FEF-0E9B1A3DCA6D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBF04D85-16FE-4392-BAA3-393C676C0B40"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF064F23-7A86-413E-8EA7-CEBFFF5889FF">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Capecitabine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D796510F-9940-48A9-ACF7-3A42A6DAB933">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC309F61-F4BA-465B-BAB9-9C78A9178FAE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:21D39AD5-687C-4933-9EC1-8D411EEE4DF8"/>
    <pav:lastSavedOn>2014-08-10 21:57:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C4D4FB4-3EB6-430F-BC08-637D2E095D79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBF80EB5-5867-4378-8F30-8764383B5F42"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D79ADB35-0606-4365-AF87-AA29A89CD77C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0E10174B-0219-43D3-A90E-3CDFE00538DF</pav:previousVersion>
    <pav:createdOn>2014-08-10 21:53:43 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5059D4A7-9D0A-44E8-A4A0-7CCEDE4D1D57"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3262463-11E3-48CB-80AD-254FA5BC68EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27C8597A-EDFF-421B-8E00-B56F268B206D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA55D176-702F-49C5-B3F4-628AE90E0E1C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A96B774-6D63-4E84-809D-9CE326458668"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6C8E47C-538E-43BD-8DBF-B72C7C5D6099"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:348FD9AF-1DBC-47C5-ACFF-93B56E3FA1ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D90ED30-6F5C-44CF-B98C-C27F511E7452">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E55B392-6C61-4B90-9EB9-9EA555555D1D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8C4145B-541F-405A-97D9-77D5041238F0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26CDE94B-D998-462C-9885-E20EB5CB5EBA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-23 11:57:50 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:586977E6-FA42-41E4-A45E-F50EC131D3EE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E48ED1B-3777-4298-91AB-D77AE62BB35B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:51821848-7A49-40DF-B961-F06F99704966"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE7E5906-C054-4CC5-AFBC-4C80B78D5D6E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F778B550-CF93-48BA-AA2B-C31FCD5B5C0C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A1BD9E2-2528-4021-8820-53386159F540"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B477D910-8941-4126-90E7-507D5D492660</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-23 11:54:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DD2DB5A-AEF5-4D7C-9D40-0EDE5D80DBF8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF8EE52-6654-4BF0-A83E-59D2212994C1">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C716DD5-36A3-4102-B790-EEFDD8479171">
    <ao:body rdf:resource="urn:linkedspls:uuid:1A529F9B-BB09-4226-B859-5957E0612554"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35666F56-D1B1-497D-AB6C-BD5EFD747D6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB06DF4A-6F26-409D-BB3A-8A01E4B34C0D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-10 22:07:24 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7F17286-FB75-48FC-A688-AC8AAFDD0EB6"/>
    <pav:createdOn>2014-08-10 22:07:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC4553F8-50E9-48FE-8430-0D301DE2E7DE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D074A4B7-8AB5-4B76-BFC3-112769F91310</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:00E533CC-9E0A-4875-87A4-43C3C4D56B23"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F737D4DC-5A36-440B-91D8-76894236E232"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36D4BB19-CD41-40DB-A590-DF3ACE4A001F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:944D45CF-CD4D-4D1F-9774-4B161B17A3D0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4605EFB7-4F03-4AB9-8DC9-4D9B4782381C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:12E4CAC0-7F66-468F-8C2A-B6F55FD2596A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8A250D1-1146-42CD-8A54-D943B9E00644"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F25644F-CDA4-4278-8179-A60F89B2CC89"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4D7DAE8-56DD-4A33-85A4-992C189CFF7F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE43A038-2DA8-4D99-981D-214332A7F7C0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CF02485-5245-4315-841B-AF795A211207"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A026AEA3-3F53-4917-90B1-26247C59DE43"/>
    <pav:lastSavedOn>2014-06-23 11:51:03 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:E86C48E0-A14E-402F-88F3-6EECABF732E6</pav:previousVersion>
    <pav:createdOn>2014-06-23 11:51:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DCA468F-F5EA-492F-A41D-EBA335355CAF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:38F3F61C-AEB5-4D37-A01A-754F6DB5B6D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:78BC8B81-3B71-454A-B26D-897291620340"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:911C0C58-84E4-4EEF-87E7-47D9336DB7DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1155018E-438A-45A3-91CB-3ACEAB3A5582">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:836049B1-A0FB-436F-9DBB-6E23FF2B22B3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:836049B1-A0FB-436F-9DBB-6E23FF2B22B3"/>
    <pav:createdOn>2014-06-23 11:39:27 -0400</pav:createdOn>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>836049B1-A0FB-436F-9DBB-6E23FF2B22B3</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:630171C7-516F-4D9F-AFE2-922953BD73B5">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76DCD01C-EACD-4FE2-B931-F749126BAA57">
    <ao:prefix>) in combination with infusional 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%.  Grade 4 neutropenia was observed in 1.8% of patients homozygous for the wild-type allele. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76DCD01C-EACD-4FE2-B931-F749126BAA57"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In another study in which 109 patients were treated with CAMPTOSAR (100125 mg/m2) in combination with bolus 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%. Grade 4 neutropenia was observed in 6.8% of patients homozygous for the wild-type allele.</ao:exact>
    <domeo:uuid>76DCD01C-EACD-4FE2-B931-F749126BAA57</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-10 21:58:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D602D554-6760-45E1-AEF3-72D46A000D8B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304642b062014642cf8be10000">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:email>acockerham01@gmail.com</foafx:email>
    <foafx:firstname>Alex</foafx:firstname>
    <foafx:lastname>Cockerham</foafx:lastname>
    <foafx:homepage></foafx:homepage>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:name>Alex</foafx:name>
    <foafx:title></foafx:title>
    <foafx:middlename></foafx:middlename>
    <rdfs:label>Alex</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302">
    <ao:exact>Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive)</ao:exact>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BEDD80D-4265-4FCA-A0AD-DCC8A5047302"/>
    <pav:createdOn>2014-06-01 21:01:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E134F90F-BB98-49F8-BD92-80628CBFDFCD">
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <pav:lastSavedOn>2014-08-10 23:53:50 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:41E9C212-448C-48B6-B598-B84492BE6DF6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:626DAB7D-59CD-40B4-9276-F2E8408C084B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7691AE7C-224B-4543-B17C-D604B3F149F0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2862160E-0C90-45F3-A1C3-CD3359CC6B47"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22B6B7B7-1C06-4D87-9D94-878BABBA422C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:59B04B6B-FA6C-4EFE-9F81-8CDE5C500E0B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-10 23:53:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C534AB6B-3248-491F-A5F1-F1E88408C5A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF4DFBD8-3AE3-44AE-93A9-B7C47ED50540"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFC5FB64-7D92-4E3C-9B93-7194C4840DCB"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B62E056D-BEFE-40B8-97D8-CC920D54F3E4">
    <pav:lastSavedOn>2014-08-10 22:05:54 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-10 22:05:50 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9949262E-8BE7-4F5E-AD93-41E04F76FE41"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C39973DF-3681-4FBE-ACBC-79FEF9643453"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4ECB73F8-17F3-4625-9FEA-64F11014F951"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FFCD594-8C77-4912-A53E-60054B826620"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF63EA96-E9D9-4793-9240-BC5E99A6F4AF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8CC33F91-5763-421E-A697-1E4AA0A0AB6C</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8B35DBC-3C9E-4920-979E-539C65C5C727"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:793B8BBA-0114-4E55-961B-4B4093C70479"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81">
    <ao:item rdf:resource="urn:domeoclient:uuid:E14686CF-A588-49E9-83B3-334780748182"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E85BAB5-4509-4E83-8CA7-75A9A691FC69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3847D7EB-4227-42C4-B28F-B22DA27F48C3"/>
    <pav:createdOn>2014-08-10 22:30:27 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:81F19A65-E4FC-4F8D-B79A-06D61BAA7316"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:8ADA1B65-540A-4556-95E0-06F41CEF84C3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B4EC10A-9E0A-4112-8F47-278513A77774"/>
    <pav:lastSavedOn>2014-08-11 00:00:16 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:761D10AB-D230-49B1-BDE0-F8D8E24E217E</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF8F937F-F74A-4727-BA25-D1D70CE84F1C"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N42cbc0d5672e4338842f20f82c88c906"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:28524DDF-1120-477E-BDE8-BA2F0884A294"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E134F90F-BB98-49F8-BD92-80628CBFDFCD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:77BD4006-9BD4-406D-9E18-6230A98A1462"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D224A37-870B-4566-9300-3CA34F697E87"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7710276-C3CF-4F0D-8858-38F6F53477A3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AC92979-425D-4E64-A80C-49DD2C75EBD8">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10DE53A3-0606-4583-BA2D-25D07EA38D58">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC560B3F-80E8-45DF-8C22-E3764D8A78E3">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F">
    <domeo:uuid>BED33609-E929-4486-9EAC-0B963C21CC8F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole strongly inhibited CYP2A6 and moderately inhibited CYP2C19.</ao:exact>
    <ao:prefix>onide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. </ao:prefix>
    <pav:createdOn>2014-06-01 20:33:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B815268-BD7A-4C42-94FB-72A1EC3BBF19">
    <pav:createdOn>2014-06-01 19:37:29 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A358766-A107-42A5-BE6E-8F31F1BA691B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F0338DC-F37D-4C91-A293-A18AE7C2CEFE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4BEBC8C-59E1-45D8-A859-F4F60A0A4C4E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F58EE64-7DC9-495A-92B7-AF8B1CD1EC2E"/>
    <pav:lastSavedOn>2014-06-01 19:37:33 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B7B24D6-F8B8-41EA-BC3D-19496AE00103"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:351BC453-B1E8-429D-9160-EB7AC9985DFA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:21A69B54-0A85-4DDC-8458-D6A971254E87"/>
    <pav:lineageUri>urn:domeoserver:annotation:BC713600-2DF1-4FCA-9023-2A4692969052</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:83EC8223-68B3-412B-BFB7-2EA2AB70681C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0271F8DE-EF25-43F8-A34E-E34F28B73616"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DCDF13F-D4DF-457B-8941-06DC89D9BDEE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC57C085-7B4C-44C1-A2D0-5A7911093AC6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:146074E6-D887-4B6B-A91C-D2BF04FB29EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DCA468F-F5EA-492F-A41D-EBA335355CAF">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF309D00-40A2-4373-9F6D-9B0EF7F83113">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7CD345E-09A1-47B2-B5D4-517A0F033D8C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-09 20:44:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF5B1B86-3B07-49E5-BF20-8CD6F84E663D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CE2B47D-C167-4209-AA0C-3C4EBC4ECE65"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:651715CC-218D-471B-B935-8C20D7F158A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6ACE7D97-748C-4A09-A70C-305797C988E5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4E2AC9B-4244-4885-9DC2-2B361565B06E"/>
    <pav:lastSavedOn>2014-08-09 20:44:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57EFC962-653B-4E28-8298-89EFD1EDAA95">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A7B917-A122-4B38-B666-8BFEE9FD1385">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F691598D-0180-4ECA-93E6-DAA5BF3618E6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34084-4 ADVERSE REACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34084-4 ADVERSE REACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D1378C98-3880-453B-8C8E-7C875F23A8C8</domeo:uuid>
    <ao:exact>Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein.</ao:exact>
    <ao:prefix>lite found in patients' plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-02 11:20:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1378C98-3880-453B-8C8E-7C875F23A8C8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED">
    <ao:item rdf:resource="urn:domeoclient:uuid:D3BEDEE1-6E3A-44BE-B2E7-1831F2CE98A5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90E5A53B-2462-4558-8CE2-4A7DFF65554A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A95CCA4-583E-427C-978E-922968ADA282"/>
    <pav:previousVersion>urn:domeoserver:annotationset:41F4EC9D-3ED3-4230-AFB1-17CC7C0B7AD0</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D90ED30-6F5C-44CF-B98C-C27F511E7452"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:23B4436A-E71F-420D-B1E1-9420C3356D28"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:B77785EF-DE8D-41E0-B5D0-E667FBF3B656"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:97B5AD14-0C9D-40EA-B0AA-DA1E709A75E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0CF72A32-62A3-44B4-8085-2A3743064FB1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2A29FDE-1792-4A92-88A1-2A747318521F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9248F74-5362-4BCF-AE17-0776F97727F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:68EEF7BA-9B61-4E29-A647-F27CEF6A0C9A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4605EFB7-4F03-4AB9-8DC9-4D9B4782381C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5577C812-C730-4655-82D1-53CF57390002"/>
    <permissions:permissions rdf:nodeID="Nd298722e097b4d27ba310aeeee12c500"/>
    <pav:lastSavedOn>2014-06-23 12:13:38 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:9256A7ED-564A-4D27-85A7-9C2759B66DD0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B02C2ED-0A83-47CF-B19A-912D8D9F24B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:613DE0CD-E412-4612-94E8-65A0CD564D72"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <pav:createdOn>2014-06-23 11:37:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61DB2955-E3A3-4920-BFAF-9CC063073BD3">
    <ncit:Alleles>CYP2C9*2, CYP2C9*3 </ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-01 20:55:48 -0400</pav:createdOn>
    <ao:exact>In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:prefix>inistered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:613DE0CD-E412-4612-94E8-65A0CD564D72">
    <ao:body rdf:resource="urn:linkedspls:uuid:EE3F7756-C92E-42ED-9AA4-26948D671E54"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:43931AD4-BEEA-4BC8-AA5D-CADF429BA9A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4C62951-37E6-4AFA-87DE-9E72DB44B268"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-23 11:57:50 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F752A03-E83D-4F05-BFA5-733989528DC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B6A567A-02D0-4DF0-93D0-7EE0108B7492"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B477D910-8941-4126-90E7-507D5D492660</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC92C403-A358-4166-9C88-260062DEA659"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D7A889E-54B0-4493-BC62-5D2D79894A46"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CC4F394-A7AE-487F-8E39-26BA985A73C4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFDB86E6-8AD1-4119-89A0-128288422892"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A301196-021F-4EE3-B07C-470C0C57EBDC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:21D08972-D7E1-4EFA-A34A-DDE979260133"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2014-06-23 11:56:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B78860AC-3C6B-422E-94F7-069AA1226270"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB740418-B021-4E92-901A-49B4D3119A5D">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C856BE8E-DEA3-4EBC-BAE5-826826C36CF9">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>I see that you all had ESR1 but have no idea where you found that information on the label.</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E55B392-6C61-4B90-9EB9-9EA555555D1D">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A7F3E5E-6959-4CA8-96DF-BDA1088E6D85">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08A2680D-3FFF-46DD-B0BF-1F3AC550FA86">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF892B93-6F38-4AC8-ABB4-ADE45FE17C3B">
    <pav:createdOn>2014-06-23 11:52:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>AF892B93-6F38-4AC8-ABB4-ADE45FE17C3B</domeo:uuid>
    <ao:exact>The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF892B93-6F38-4AC8-ABB4-ADE45FE17C3B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71">
    <ao:item rdf:resource="urn:domeoclient:uuid:7ACC8015-77AD-48A6-B400-638BFB942409"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC963D6E-86F0-41A8-BBB4-F5713CDAB9AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF309D00-40A2-4373-9F6D-9B0EF7F83113"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2662590-EBA5-4EF7-BFB4-8040243ED1B3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N92b2bbd591074e989703ab27234f0de5"/>
    <pav:lastSavedOn>2014-08-09 21:53:10 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE0FFD2D-D369-494B-833F-337DB6A99036"/>
    <pav:createdOn>2014-08-09 20:39:15 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1B911F4-D233-4E93-B176-8CEEFE47489F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B0770A34-42E4-4D3B-8AED-154FDB4FDE79"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C8F35CA9-7C64-4702-ACB7-144CDE0BEF37</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:614FD391-7B36-429E-BE37-CC28603291F6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:040E1451-9494-4650-9EE0-23B7302B057A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42F81A77-1DDD-48FA-992B-C3B0338BF505">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:DF8718B3-5DB9-4830-9C2C-9448331E11D2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8737CA6E-9A94-4D4D-B020-9D3A98915AB1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B716172-F68E-4EFB-9A90-7067FE508F97"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C5E848BF-095A-4FC4-B7FD-060C52D72F66</domeo:belongsToSet>
    <pav:lastSavedOn>2014-08-09 12:35:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE7DDEB4-B524-42A9-A555-BF280A81D168"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AC92979-425D-4E64-A80C-49DD2C75EBD8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3BEFDA7-8A18-494B-B506-AA2F2DD504AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7E05FB0-37B2-4601-A2FF-95A3B9FFFB28"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-08-09 12:35:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF894966-52DA-4712-A6F7-2E418E0E66C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:046E02CC-B43C-460B-B30D-89DC3C4C51E2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DA1AA1D-8283-4F46-95E0-D8738048383A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD0BAC3C-A21B-4C48-8C09-8B0B426B2E68">
    <pav:lineageUri>urn:domeoserver:annotationset:E69D5D39-08C2-4F6A-82D2-9BB1F2BAE7B2</pav:lineageUri>
    <pav:lastSavedOn>2014-08-09 20:21:01 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:62CF9D0F-F138-4528-B2C3-F4C7D3D6F71A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E645C77C-8BC4-47FE-B696-8385699C98BC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA854708-62EF-4C38-A8D4-DCF90367088F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D14C1107-3ED0-4351-923C-D114C4559F07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7054B823-EEB9-4382-A2A5-3B431182A090"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D8090C8-06F6-4036-A295-0A093E356489"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:89CAE038-F224-48D4-8F50-A0118B7242FF"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:613A1FEB-89E1-4409-B873-D77B591CA651"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-09 19:59:58 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3672CD89-8481-45DE-B9C2-D28EBE22060E">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Should this be more than one annotation?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FAC52E6-4633-4679-A786-5EDE285F0789">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A881CD2F-30B9-4C63-B79B-80131A3603C2">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:468FE543-AD1E-48C2-AEC2-929DA27DC15F">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:246FC7F0-0FDD-4242-9C08-71340FAEBED2">
    <rdfs:label>Required</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D14C1107-3ED0-4351-923C-D114C4559F07">
    <pav:lineageUri>urn:domeoserver:annotationset:E69D5D39-08C2-4F6A-82D2-9BB1F2BAE7B2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7AE4498-0791-430D-971B-593DFED47C18"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:annotatesResource>
    <pav:lastSavedOn>2014-08-09 20:21:01 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>urn:domeoserver:annotationset:38056B26-0856-4B1E-BE3C-B4B36B8B6DDE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-08-09 19:58:49 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F653188-E3F2-4B37-B6D6-E7EA7F7FE727"/>
    <permissions:permissions rdf:nodeID="N4a35323a88fe4ed78858a67fb140f8f5"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD0BAC3C-A21B-4C48-8C09-8B0B426B2E68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E933301-5FE2-4827-85D6-3D71B5A93C82"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F8B5277-C411-4FE5-998F-6BE4513B3692">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CFTR G1244E,  CFTR G1349D, CFTR  G178R, CFTR  G551S, CFTR  G970R, CFTR  S1251N, CFTR  S1255P, CFTR  S549N, CFTR S549R, CFTR F508del, CFTR </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB5A86FB-B345-4E1A-8900-8DEEEA090BF2">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA9E42CC-F1E7-4CFD-AED6-F74E23CA07BD">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1483C104-1035-4F90-B6A1-E546F30356A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:063BE245-52EF-45FC-8786-26709F5717B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C94E7B6D-85F6-4A00-8BE8-CCEEA58A9D9C"/>
    <pav:createdOn>2014-06-01 20:26:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C142C80C-93FC-4F4D-BB05-9AAD8A4ADFD3"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C35CE08B-2D0A-445E-8FF3-98CB7A953446"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961ABB97-90DE-483F-87EA-8A701EE196B4"/>
    <pav:lastSavedOn>2014-06-01 20:26:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:43639865-D15D-44CD-B29C-C1DE608FAC81"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E93E67E-7C76-44BE-AFE1-D5AE75C92344"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D575317-A42D-4650-BD42-0877F98B72F9">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FAC7603-5023-4D0C-AB60-484403F16245"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8AE2753-37D4-4732-9BDC-A8BCBDC66097"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:619014FA-87B2-4D3C-9270-E7257598EEC8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9704EE13-B090-4512-A4E3-F8DDD0AAB50F"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lastSavedOn>2014-08-10 21:29:11 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:92D2D6D8-0F82-4CCE-ABC4-76D19D843E6F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:55EEFAEE-05B7-4F9A-9ACA-C116E05AD138"/>
    <pav:createdOn>2014-08-10 21:28:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E62731A-C2B9-4F21-8C00-1CFEEEB0CE99">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:60AB858A-177D-4161-91FD-6FB672AE1AC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67D77FED-0781-4E61-8DBB-F4CB65833749"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32A43506-436E-45E7-8BEF-AC69213D3AA9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0E10174B-0219-43D3-A90E-3CDFE00538DF</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:lastSavedOn>2014-08-10 21:57:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3389A5A7-41C0-4E07-9A32-59D66D1B3750"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:78D36F0A-2543-4ACB-B09D-3C3A84A6F928"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99C32C61-7BC3-4B93-872A-CCDF4689D717"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:09D2862B-D8FB-4E09-9821-80C159195148"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94D136B7-11C7-4F96-99E9-8788AB0C1DB6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD9AE446-7531-4F62-A4EA-04CDB3668590"/>
    <pav:createdOn>2014-08-10 21:56:16 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:478593EF-EF81-45E0-816E-06CD19C7B600"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:181A738E-65CA-4CF8-837C-CF3C74EFD546"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A14343D-5DC1-4861-9651-2DCE58B59689"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C895D7E-E97D-4CC6-9FC9-7EF9E64CAB4B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BED2D48F-56C7-41B5-8920-32197D90ECAF">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-negative</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8613DBE-E23B-4505-97DC-D1A8904A9B30">
    <rdfs:label>BRAF</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF8F937F-F74A-4727-BA25-D1D70CE84F1C">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E4CFCEC-52F1-4DC3-8C7D-958E0CBB0930"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BE4D17A-C226-4AFB-A8B7-25943C052F09"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-08-11 00:00:11 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A851F571-49BF-4678-9A40-61D2E3DC06A2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8C502EF-8F14-4202-BFF9-463CE5DA169B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B7C227F-856D-4CF2-A4C0-EED0DEC4B506"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:94D9256D-C0E3-49E3-819C-83865B32A874"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-08-11 00:00:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:3D9683F8-B507-4BD9-B549-4709B20ECD3A</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ADA1B65-540A-4556-95E0-06F41CEF84C3">
    <pav:createdOn>2014-08-10 22:41:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3DEDAB0-2203-467F-A767-BF51E2926DD7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3962F73F-9B04-454E-BFA8-92F762C8334D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:744677B2-4EB0-44F1-B7CB-E8D281EB0F80"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B753E620-7EBB-47DA-B58E-180DB71FC231"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-10 22:43:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F10EFFF-945F-4AEB-92CC-57E417F7F69A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0557748A-C39A-46DA-BD25-3544CCCF15DC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D26531AA-6B60-402A-8811-F888FC608BDC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A881CD2F-30B9-4C63-B79B-80131A3603C2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B83771A3-17DB-4346-B9D3-E8DEA72C9BCB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B83771A3-17DB-4346-B9D3-E8DEA72C9BCB"/>
    <domeo:uuid>B83771A3-17DB-4346-B9D3-E8DEA72C9BCB</domeo:uuid>
    <ao:exact>The recommended dose of Gleevec to be given in combination with chemotherapy to children with newly diagnosed Ph+ ALL is 340mg/m2/day (not to exceed 600mg).</ao:exact>
    <pav:createdOn>2014-08-09 20:58:47 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E7D9F2D-657A-4D1C-A6F7-50F65349E4B6">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8E7D9F2D-657A-4D1C-A6F7-50F65349E4B6</domeo:uuid>
    <ao:exact>KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E7D9F2D-657A-4D1C-A6F7-50F65349E4B6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-10 22:34:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8737CA6E-9A94-4D4D-B020-9D3A98915AB1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:hasSource>
    <domeo:uuid>8737CA6E-9A94-4D4D-B020-9D3A98915AB1</domeo:uuid>
    <pav:createdOn>2014-08-09 12:35:38 -0400</pav:createdOn>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>In addition, certain drugs inh</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8737CA6E-9A94-4D4D-B020-9D3A98915AB1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:586977E6-FA42-41E4-A45E-F50EC131D3EE">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3B18E66-3D1C-4FC4-9C87-0991DA7E46F7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5  ???</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B753E620-7EBB-47DA-B58E-180DB71FC231">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:suffix> (</ao:suffix>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B753E620-7EBB-47DA-B58E-180DB71FC231"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-10 22:41:50 -0400</pav:createdOn>
    <domeo:uuid>B753E620-7EBB-47DA-B58E-180DB71FC231</domeo:uuid>
    <ao:exact>Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St. John's Wort) substantially decreases exposure of ivacaftor, which may diminish effectiveness. Therefore, co-administration is not recommended.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB320B68-62FC-4457-B449-7E0CD9890D51">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7ACC8015-77AD-48A6-B400-638BFB942409">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF4D4B11-F8EC-4658-B8D0-687F5D34C9E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5ABEDBB-1537-4826-8A67-D1D682B8E8B4"/>
    <pav:createdOn>2014-08-09 20:42:29 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:345DA299-9F71-4050-A1FA-233E968A208F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F2E59F3-E967-44CA-8CFB-87772F1A6B4C"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:657F04C4-DF90-4589-8E67-95EA5B343A04"/>
    <pav:lastSavedOn>2014-08-09 20:44:31 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5F34B00-9314-4FDD-8D6B-4F611AB89216"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3783BF66-40FD-4C55-B4D6-62A054C85BA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7028FEDD-7155-405A-A774-8FCE4035A758"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:641CB75A-B08D-4C90-8629-2BABDCC233BE">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The recommended dose of Gleevec is 600 mg/day for adult patients with relapsed/refractory Ph+ ALL.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:641CB75A-B08D-4C90-8629-2BABDCC233BE"/>
    <domeo:uuid>641CB75A-B08D-4C90-8629-2BABDCC233BE</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-08-09 20:50:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4BEBC8C-59E1-45D8-A859-F4F60A0A4C4E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2FB69F2-D2FF-43EF-8D5C-29732917A825">
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:46F6BA9D-79BA-48A7-91D5-BBFC46775697"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:451D05CA-4BB1-46B3-81DE-57753077DCC2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:057E63DB-B25B-4E76-9FB2-B358F7686200"/>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A51DC49-F45F-4CA3-A6F9-06104CA8B14C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C478D95-94FE-474B-B9ED-AA77113212FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7044D8AD-2E9A-4764-8005-C08DC9ACB3C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82A863E2-4600-4792-BDAB-897D7BCBB8A7"/>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:85062DD4-AC27-4671-801E-7592AC985BD2"/>
    <pav:createdOn>2014-06-02 11:47:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0E35AA6-356F-4054-945A-07801C6240FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0873D062-8063-4C54-9319-262761698F98"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A88FBF0-A260-4DEF-B583-5E9E8F918005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C2CCBFD-B80D-4BB8-A38C-039E6E9CAE25">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21D39AD5-687C-4933-9EC1-8D411EEE4DF8">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE07F18F-F19C-4F49-975C-232A47227ABA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84DB5EC5-B980-4493-82E8-5E5D393FE2D9">
    <ao:body rdf:resource="urn:linkedspls:uuid:44301F97-7088-46C4-BB32-27D413FE3A60"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECAC2FA7-FAA7-485D-A99C-271BB5D62013"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FD140441-800B-4DD9-BDDD-A11517ACBE7F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:04539A04-F082-4C33-9B14-C8B5A2B0E0B5"/>
    <pav:lastSavedOn>2014-06-01 20:55:49 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBEB0ACB-D1CB-409F-8826-3D87E728DE4C"/>
    <pav:createdOn>2014-06-01 20:55:48 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F18EABFA-DE53-4697-A79C-CE2728D2CEAF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4BD57CF8-1480-405E-BA53-593A3F7CA86F</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B901F682-13D1-4291-9125-3CD610827426"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB7F5CE5-2A4D-469D-82B4-26C64B9D23AD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B667F421-8E8F-44D2-9A57-4CC1AEDC2893">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B5E5DA48-A12E-45BE-B26B-291C933A1819">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3389A5A7-41C0-4E07-9A32-59D66D1B3750">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12247663-6D8E-4333-8FCA-0EC431436874">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C5E848BF-095A-4FC4-B7FD-060C52D72F66">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9E57895-1CBE-4C34-AB4D-AD55BAB415BF"/>
    <pav:createdOn>2014-08-09 12:27:18 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:42F81A77-1DDD-48FA-992B-C3B0338BF505"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:5B7C450C-9FAD-47CD-BFEC-467C389D7B56</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N25ca8a1f4a804e6781ff2a3700bf39d8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1144F11-0CA9-45FE-9BF9-96DCEBE21D9F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DF8718B3-5DB9-4830-9C2C-9448331E11D2</pav:lineageUri>
    <pav:lastSavedOn>2014-08-09 12:43:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3262463-11E3-48CB-80AD-254FA5BC68EC">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-10 21:57:06 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C3262463-11E3-48CB-80AD-254FA5BC68EC</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In a study of 66 patients who received single-agent CAMPTOSAR (350 mg/m2 once-every-3-weeks), the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%. No grade 4 neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3262463-11E3-48CB-80AD-254FA5BC68EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FEB6CAC-68D2-4C9C-972E-4494AE232800">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FE44853-CB4C-40F8-BB0F-58A8B6FD9E88">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDEC54E1-AF7F-4766-992E-F0C0D8B346C1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA352C73-C1EA-4D7D-AE35-0CFDE97E6F6F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B15AACC-C1D4-45B5-96D6-FBB023BC5F3B"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3CB14A4C-8812-4724-A0EC-5FBD71584EFB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D9E4522-945F-4A0F-9E1E-DA98FE8B3BDC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1E2C8EC-EDF4-4FC4-B7CC-24E7ED0C5310"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B5827AA3-0BA3-44C0-BB2B-FE3580D7D73A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5D5A83A-B881-497C-989F-283E7BB1F539"/>
    <pav:lastSavedOn>2014-08-10 21:27:48 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-10 21:27:44 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8DE17B6-B1FA-4A3F-B3AF-F7565E42FD98"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE8B58F1-C9BC-407F-AF74-514C8148B892">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Ancestry</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9E57895-1CBE-4C34-AB4D-AD55BAB415BF">
    <ao:body rdf:resource="urn:linkedspls:uuid:3EBA90CA-E217-4D55-B7B6-63C5FD55B5E0"/>
    <pav:createdOn>2014-08-09 12:43:16 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B43F403A-1CD9-4FFA-806C-F701F89641FF</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F90BB48-9E97-4846-A924-6BDE2BA21548"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A96D2815-77CE-4604-9C8F-5A96CA42E025"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C5E848BF-095A-4FC4-B7FD-060C52D72F66</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B12A4A3-E829-46B1-B700-EE35E9CFE6D2"/>
    <pav:lastSavedOn>2014-08-09 12:43:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:475179DB-17CE-4C9C-B063-3C6AB85F1E4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7023AA5-1DAE-4A0B-A217-69F8C8A1DFCC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:75643664-2DC3-4767-9EE6-7CCAA29DA216"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:34B06981-AD0F-44A1-BD68-B4BA60859FD8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A0FC3DC-9928-45C0-BB39-67AF50042771"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C64AFC4-CF3C-4E4A-97BD-7D4B7BF6C096"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3353B039-964D-46C9-8693-7B6C85A1C742"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>71923767-C4E7-42DE-84F8-01605D56F151</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151"/>
    <pav:createdOn>2014-06-01 20:15:14 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23B4436A-E71F-420D-B1E1-9420C3356D28">
    <ao:body rdf:resource="urn:linkedspls:uuid:FF99415E-699B-49E4-B42D-8C12C707766C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A133F4C2-702C-4A40-BF70-F7A8C2059EDE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26ED1574-E13A-4959-9E4F-45BE4BDA351E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:189E8CA1-5263-4DF9-B8BB-A0969A5A2277"/>
    <pav:previousVersion>urn:domeoclient:uuid:A7AF9F89-DE14-400E-B4F3-8C885F77B479</pav:previousVersion>
    <pav:lastSavedOn>2014-06-23 11:47:09 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:23BD8DF3-C5D7-4B70-BACE-FD2C81662D9C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3700E10D-A41A-41CE-B5E9-C568C9A79178"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CA122B4-F5F4-47B5-B5A6-4EE8F03DE5BA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE8B58F1-C9BC-407F-AF74-514C8148B892"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:50DC0725-A112-4C63-82E0-3AE9A8BFD396"/>
    <pav:createdOn>2014-06-23 11:47:09 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B0F98E5-9941-4185-80B8-29A789540691"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D602D554-6760-45E1-AEF3-72D46A000D8B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24950A77-AA81-4C28-864F-AEDA923C8518">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8650AFA8-B61A-4A92-A987-B371590DFBCE">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD9AE446-7531-4F62-A4EA-04CDB3668590">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95F033BF-10B1-489F-B523-1E9063A71F38">
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E099BC1-7905-4F64-8057-156FC53ADB58">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1144F11-0CA9-45FE-9BF9-96DCEBE21D9F">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:33882B0A-6CEE-4FA1-A9E0-996AD46C70AF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:066D80FC-F8B2-4D72-8338-3DC5AD62AE34"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1591CEC1-2E0C-4312-B4F1-C0D0F14BB0BC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7B7C87B-58AA-4F8C-81B4-DF55D622D0B8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:964268AF-4FE2-48DB-9262-846359807A55"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAE5BAE6-F9FD-40B0-88DA-1DFD96F59585"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB4A64F3-9026-443B-A0F5-49B5AF1CEA56"/>
    <pav:lastSavedOn>2014-08-09 12:43:25 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:D549B288-CBDE-42F4-BB28-D089685AE327</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C5E848BF-095A-4FC4-B7FD-060C52D72F66</domeo:belongsToSet>
    <pav:createdOn>2014-08-09 12:40:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BEF81E9-82FD-450A-8BDF-59AFEFE9B8EB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F33AF78F-8D13-42EE-B8C1-8C92CD33E60F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FDE2809-7490-4004-8ECD-428B36F48B79"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9079CD80-B336-4A30-A2A1-47B7530408B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A36D52A9-2A1C-46F3-92DD-39141B9A088A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE">
    <domeo:uuid>63CB3359-94D1-40EE-AF4F-853814B8E2BE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:17:53 -0400</pav:createdOn>
    <ao:suffix>[see Clinical Studies (14.4, 1</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4883DD92-91BF-458F-88A5-E2857AE33002">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4883DD92-91BF-458F-88A5-E2857AE33002"/>
    <domeo:uuid>4883DD92-91BF-458F-88A5-E2857AE33002</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-09 20:20:45 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:exact>Other than warfarin, no formal drug-drug interaction studies between XELODA and other CYP2C9 substrates have been conducted. Care should be exercised when XELODA is coadministered with CYP2C9 substrates.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:742D9FCD-2D9A-468B-B1DE-2EA9C3786782">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35FB2E8E-AD51-4F49-993D-2C68F0FDE171">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E80AFBE-0A52-4745-AE9E-9AB372773FFD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D075A98A-6E8D-4058-8053-C50ED33E10AC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1643D737-5188-4795-9C3E-1361D4D71262</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 20:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CC422AD-3150-4062-B2B7-734941FBC7FA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:33049BC0-4665-43EC-8226-84723CC7AC54"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E22833FF-9C8C-4AAF-BF61-7A1BAC88B9EE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:339670C1-0475-4E89-9865-932C014CDE44"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:669C65A2-428A-40D8-AB6B-42D149C8F608"/>
    <pav:createdOn>2014-06-01 20:27:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1461839B-2331-4FA6-B624-FD2100276C0D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9A48574-7F84-4D1C-B3B1-C7F5BD271B81">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C6C1DB3-50EA-4E8C-9744-0620557B06F4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:05EA9C6C-754C-4764-A879-E4CE913428A2</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 20:12:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:45BA0CBA-7217-4D45-8C6B-F3247F353A9F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:77163E48-FDB2-4C0A-A127-B74C2095634E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C856BE8E-DEA3-4EBC-BAE5-826826C36CF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8840FB3B-47B3-4958-864C-619B7A4F6927"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82B4B70A-A7ED-4A04-9BB4-206EF37C2508"/>
    <pav:createdOn>2014-06-01 20:12:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B2E425D-1901-4350-941B-9E3FF9C34BF9">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:046EE207-4499-4C25-8AE6-81689BAB026D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6734B02-ECA2-4C72-BF40-9F8C068486B0">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EA68AC5-1674-484B-B8D0-2AECA70B9FE8">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94D9256D-C0E3-49E3-819C-83865B32A874">
    <pav:createdOn>2014-08-11 00:00:11 -0400</pav:createdOn>
    <ao:prefix>F508del Mutation in the CFTR Gene </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Efficacy results from a double-blind, placebo-controlled trial in patients with CF who are homozygous for the F508del mutation in the CFTR gene showed no statistically significant difference in forced expiratory volume exhaled in one second (FEV1) over 16 weeks of KALYDECO treatment compared to placebo [see Clinical Studies (14.3)]. Therefore, KALYDECO should not be used in patients homozygous for the F508del mutation in the CFTR gene.</ao:exact>
    <domeo:uuid>94D9256D-C0E3-49E3-819C-83865B32A874</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94D9256D-C0E3-49E3-819C-83865B32A874"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8B35DBC-3C9E-4920-979E-539C65C5C727">
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97B5AD14-0C9D-40EA-B0AA-DA1E709A75E3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91B3B532-B1D4-4608-B8A6-50E42526D8E0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:254E53F4-ADF4-4713-938E-1C0386D7A5E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F0C0FB9-DF19-4D6E-949F-6ADC00A8977C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <pav:createdOn>2014-06-23 12:05:30 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A1366B4-29EB-412A-B68B-B95F336BAF7A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:391B05C5-B412-4155-80AD-9318BA217C9B"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:261DB21A-00ED-42B3-A086-14062057B96A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81B49A95-D438-4609-8F7C-C3A0DFE821FC"/>
    <pav:lastSavedOn>2014-06-23 12:06:14 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C4D6D414-7EDE-4B56-A45C-30F5A0023D11</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:18131683-7CC8-445D-8167-63ACA1A3B3D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:852C6E07-7D0F-4759-B60B-2F84975DE3EC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B590989-98A9-4FC3-9F06-44D7192C82FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D2AE312-F185-429F-9003-FDA4E74523C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6894BC08-84DE-4272-B1B2-1CCDD5AF8ADD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:563D84AA-9BEE-4BA8-8D08-3A4F5F473A1F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C49E36DE-5ECE-4AE4-8054-4C31FF132938"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:62C44EE7-9565-49BB-8348-F00484C13CA9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:43BE40DF-E3A1-4B18-861F-5F151D1E6E92</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5F0D7FB-E816-4314-B450-214BD51BDA11"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D2D084F-6A5B-4E87-9B36-958F2E5BA705"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-06-02 11:40:20 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-02 11:47:08 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B49A8982-2AC0-4EB5-B28A-FC33CF719F1A">
    <ao:exact>When administered in combination with other agents or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B49A8982-2AC0-4EB5-B28A-FC33CF719F1A</domeo:uuid>
    <ao:suffix> [</ao:suffix>
    <pav:createdOn>2014-08-10 21:59:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B49A8982-2AC0-4EB5-B28A-FC33CF719F1A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1B911F4-D233-4E93-B176-8CEEFE47489F">
    <ao:body rdf:resource="urn:linkedspls:uuid:A9ACFA9D-1F43-40DC-804F-548CA84C099D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF266C1-FA4F-4B1F-AEE8-A51CF72207CB"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:704A2F41-D55D-43C7-8C57-73DA2EDA6EF6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:33E8EA8F-B9E5-40E3-8665-37032B0ED7C5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B83B9EB1-3805-4C0B-9F4C-DC28B04420E5</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A81D2EF-029A-415B-B597-6299C70A58C8"/>
    <pav:createdOn>2014-08-09 21:53:04 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFD6D71F-C2BF-4A93-AA87-5ED9808A94CD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <pav:lastSavedOn>2014-08-09 21:53:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28524DDF-1120-477E-BDE8-BA2F0884A294">
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:867A2668-77BC-4F6A-987C-114E9D9549C9"/>
    <pav:createdOn>2014-08-10 22:43:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AE58537-F6FF-4692-BBCE-D614E552418A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C5D336C-1591-47DB-9267-FBB2AE135DC2"/>
    <pav:lastSavedOn>2014-08-10 22:43:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB8775C1-7B43-429B-AF1D-3BB7F8D10798"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0557748A-C39A-46DA-BD25-3544CCCF15DC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:88EE3C83-F59F-43AE-B4CD-71A4C44F1E33"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB356CAD-C0F8-4B4C-9C25-8CC9A8604A8E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF6E49B3-BB09-40AD-9D47-A996FC2ED92D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3FE67137-DFCA-4572-B7FC-D2EF3A58416B">
    <ao:exact>Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment.</ao:exact>
    <domeo:uuid>3FE67137-DFCA-4572-B7FC-D2EF3A58416B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3FE67137-DFCA-4572-B7FC-D2EF3A58416B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-08-10 21:44:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>In a study of 66 patients who </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83EC8223-68B3-412B-BFB7-2EA2AB70681C">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C142C80C-93FC-4F4D-BB05-9AAD8A4ADFD3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FFCD594-8C77-4912-A53E-60054B826620">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA67AE32-4F6F-4E1B-982C-3C410618CAC2">
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B46F04DC-85C8-4982-8ADB-7231FDAE4913">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6">
    <ao:item rdf:resource="urn:domeoclient:uuid:D796510F-9940-48A9-ACF7-3A42A6DAB933"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:605637B9-912E-4844-8BE8-343B87CE069B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FFD9A22-13CF-451C-B6FF-43DB04F9F71A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C716DD5-36A3-4102-B790-EEFDD8479171"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:80367309-A4CC-4A89-A00C-C8EA929D52F2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E62731A-C2B9-4F21-8C00-1CFEEEB0CE99"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08A53415-7699-4FDC-BDCA-84A6BB818418"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D59960C0-DE13-45D1-AED5-55D634B36617"/>
    <pav:lastSavedOn>2014-08-10 22:20:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nddd1e6b254364ab1a863f18da95610c7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:18657172-C867-4D85-B776-51685EE9ED5D</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB5FBDC0-F925-435E-8365-1ABE9E5C1500"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BD38BB9-E595-46B7-AFF3-42EC7BDCBC08"/>
    <pav:createdOn>2014-08-10 21:24:29 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B62E056D-BEFE-40B8-97D8-CC920D54F3E4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D220057A-D861-4B4F-9869-A27D03B3B259"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EDAF04C-683D-423D-82D0-BBF1C483F6D2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6FE44853-CB4C-40F8-BB0F-58A8B6FD9E88"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D575317-A42D-4650-BD42-0877F98B72F9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35F14E43-E525-45CA-BCC8-C962B209578C">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D59960C0-DE13-45D1-AED5-55D634B36617">
    <ao:body rdf:resource="urn:linkedspls:uuid:F75844DB-E53D-4A7E-8248-E2D1AE992D03"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DEC04D31-001D-47EB-9405-DF1CA0140971</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-08-10 22:00:39 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2783EC2F-6C89-4C26-B46B-31A86D1360CA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:79355B65-05D6-44AA-A39B-F1922D63984F"/>
    <pav:lastSavedOn>2014-08-10 22:00:44 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:43D32FD1-DA85-469D-A0E5-5FBD43C0EF54"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF5088B6-388D-4934-9857-FD769E87D8A1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9B7673C-D5C1-460F-BBC9-3E98308394E0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-01 20:29:42 -0400</pav:createdOn>
    <ao:prefix>Among these patients, 54% had node-positive disease and 46% had node-negative disease. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11D24A0D-29EE-4624-9F15-0C79D5F74ABC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A461FB23-AD27-4338-B215-B0EEB975D2FD">
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B967963-2C76-436B-9F36-EE57DE7CD58D">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06682B01-A432-4E05-8191-6DAD4683C330">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DBCFFE9-9574-432A-8429-87D7F9D0F0CF">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E008FAD-D62D-493D-800E-B4DB7F181625">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FFD0391-8E1C-417F-B431-7442EDC03CC4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B06CC265-F8E0-4C28-9939-880EF88A5101"/>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D45E220-3807-489B-B2BF-EC91BDA967CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F1D72A7-73E0-4C9B-935C-5EDCCA2982ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:BED33609-E929-4486-9EAC-0B963C21CC8F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <pav:createdOn>2014-06-01 20:33:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:99F398CF-DA8E-4ACF-A452-BAC543EA248C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF914CBA-27EE-4C33-A929-F5D51EED1623"/>
    <pav:lineageUri>urn:domeoserver:annotation:1CC417AA-FE45-443C-BE17-296F63E9FEB7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:345DA299-9F71-4050-A1FA-233E968A208F">
    <ao:suffix> Alternatively, in children with CML the daily dose may be split into two - one portion dosed in the morning and one portion in the evening. There is no experience with Gleevec treatment in children under 1 year of age.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:345DA299-9F71-4050-A1FA-233E968A208F"/>
    <pav:createdOn>2014-08-09 20:42:29 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In children, Gleevec treatment can be given as a once-daily dose in CML and Ph+ ALL.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>345DA299-9F71-4050-A1FA-233E968A208F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1784625-BB2F-4C6B-8074-9FE645D297D3">
    <domeo:uuid>F1784625-BB2F-4C6B-8074-9FE645D297D3</domeo:uuid>
    <pav:createdOn>2014-08-09 21:09:39 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Concomitant Strong CYP3A4 inducers: The use of concomitant strong CYP3A4 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin, phenobarbital). If patients must be co-administered a strong CYP3A4 inducer, based on pharmacokinetic studies, the dosage of Gleevec should be increased by at least 50%, and clinical response should be carefully monitored</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1784625-BB2F-4C6B-8074-9FE645D297D3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A88FBF0-A260-4DEF-B583-5E9E8F918005">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F">
    <ao:exact>Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mechanism by which these reductions occur; other CYP3A4 inducing agents have not been studied to confirm this effect.</ao:exact>
    <ao:prefix>Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-02 11:50:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>04514E5A-CC45-47DE-9281-2FBD57AC110F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77BD4006-9BD4-406D-9E18-6230A98A1462">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-10 23:22:23 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA67AE32-4F6F-4E1B-982C-3C410618CAC2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:62809121-0387-4AED-BAB6-89A4ABBCA85C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFE6B916-956A-471C-A188-5B6E1DE9D592"/>
    <pav:previousVersion>urn:domeoserver:annotationset:796F10E5-52A4-4AB4-B259-DF0E8B5C4FEA</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-08-10 23:22:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED7BAF5C-D6A1-4037-914B-DC48038794EF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:38B239A4-676D-417F-8FF3-8EFD527E04C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3A0C91F-5436-4E90-9D20-F2E2F3F67F14"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:04D23969-1D1F-4A9A-B1FB-3952D8158677"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A6302C7-8EF3-460C-B116-7E59FA9BE9DC">
    <ao:context rdf:resource="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:402EEAA2-F9CC-46AF-9550-E45E115692FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D032294E-CED1-410A-B8D7-381F84967E05"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9F7D401-954A-4681-9DCF-4774DD0355CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A18AC49-4F82-4AE2-B58C-9068D4CE2A8B"/>
    <pav:createdOn>2014-06-02 11:33:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F756ED20-FA04-4BDF-BC09-9FBC85BDC887"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-06-02 11:34:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:294D1B8B-6C69-42C3-B2E0-9A4F3FD352CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B9704426-CE3F-49D8-B1BA-14F8EDD6988F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:A2165F85-DA12-4AC2-A372-6EBD213B5987</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE07F18F-F19C-4F49-975C-232A47227ABA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:518D89E7-C4E7-42C6-A37E-48F86BA012B4">
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:45F7DA71-DCBA-4667-AD78-F695417EFD56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A7F3E5E-6959-4CA8-96DF-BDA1088E6D85"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:043A8FED-C2FF-4047-BA84-C4896E5062DA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:createdOn>2014-06-01 20:43:17 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B77509C-B4A9-48D8-8281-20CE902E914A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9AAB24E-347C-44AC-9337-70D4C8D31CA1"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DD38833-252C-4D6E-9B42-D0FFA4AAF4D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E59B98C-D1FE-41D7-81D3-C3A9E7617BAD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD1D3598-88CE-46BB-AE4F-E410622B3983">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B12A4A3-E829-46B1-B700-EE35E9CFE6D2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63273F2D-06DF-4FCA-8DD7-BC0DAB237B66">
    <ao:exact>There was a significant increase in exposure to imatinib (mean Cmax and AUC increased by 26% and 40%, respectively) in healthy subjects when Gleevec was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution is recommended when administering Gleevec with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice may also increase plasma concentrations of imatinib and should be avoided. Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.</ao:exact>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63273F2D-06DF-4FCA-8DD7-BC0DAB237B66"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-08-09 21:50:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>63273F2D-06DF-4FCA-8DD7-BC0DAB237B66</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B02C2ED-0A83-47CF-B19A-912D8D9F24B0">
    <ao:body rdf:resource="urn:linkedspls:uuid:93B927C1-2F20-4DBC-B29B-D1455CC09205"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:523C86B8-DDA8-4C60-87C5-0E5E7B37AB61"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F53CD0AA-C7AA-4D7B-BF7A-D18481B4C9C7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:30F29C26-29B0-4F07-84FB-96B7E6F79ED9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7BBECA1-0C77-4D3E-89CF-EBB73FABD318"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9838E62C-2417-4CE2-A1B4-B03A0F6B2C84"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF892B93-6F38-4AC8-ABB4-ADE45FE17C3B"/>
    <pav:createdOn>2014-06-23 11:52:43 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBDEA3B2-55BF-4555-AD74-97D937C09549"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9220F5FF-F228-443C-9B4F-81F507AD0EC9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A9F631A-E313-4D6A-A199-3041376B3385"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:48C45D74-0A72-4857-8E30-ED8E550324AF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BEA2D87-30DC-468E-A64B-7DD7CE2A76D7"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lastSavedOn>2014-06-23 11:52:43 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:06A3420D-A05F-4067-82E2-17543B600AA4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CE2B47D-C167-4209-AA0C-3C4EBC4ECE65">
    <rdfs:label>Ph Chromosome</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAD1465D-090B-448F-AD6B-DE55AC35DDE0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:478593EF-EF81-45E0-816E-06CD19C7B600">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2">
    <domeo:uuid>2A02EB88-FB01-4216-A878-9EE08371A1E2</domeo:uuid>
    <pav:createdOn>2014-06-02 11:54:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>if tamoxifen citrate tablets lowers the chance of getting breast cancer in women who have abnormal breast cancer genes (BRCA1 and BRCA2)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A02EB88-FB01-4216-A878-9EE08371A1E2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>citrate tablets to reduce the chance of getting breast cancer? We don't know  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C9982E0-656A-4CE6-91BD-09368A1A1F57">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DD38833-252C-4D6E-9B42-D0FFA4AAF4D1">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2CD29AE-81FF-4D58-901A-F2401931DC7C">
    <ao:exact>The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-23 12:09:26 -0400</pav:createdOn>
    <domeo:uuid>A2CD29AE-81FF-4D58-901A-F2401931DC7C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A2CD29AE-81FF-4D58-901A-F2401931DC7C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C72F6B71-2159-4110-809B-7357D0414529">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8BF8D66-ED88-4471-A73B-229532B32886">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2CE48A5-B949-4665-AEA2-11758EADAF68">
    <ao:body rdf:resource="urn:linkedspls:uuid:EDE35E41-6B9A-4949-9334-3BA2C5FC0448"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:742D9FCD-2D9A-468B-B1DE-2EA9C3786782"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D281CDBD-9057-40C6-9414-F16357D3042C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB39EC49-39E7-4F01-BDFA-DBB2A633035D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B46F04DC-85C8-4982-8ADB-7231FDAE4913"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:32C7D92F-8B7C-4FC1-BE72-43A4987726AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B12F04A-876C-40C2-BD49-80D7A1174AE8"/>
    <pav:createdOn>2014-06-01 20:41:40 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:16175971-B5AE-48AB-9C1F-13487FB63F5F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D2AE312-F185-429F-9003-FDA4E74523C6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8DE17B6-B1FA-4A3F-B3AF-F7565E42FD98">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2088FA5-4C4B-4269-BE84-0CBECDFB6D49">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094">
    <ao:item rdf:resource="urn:domeoclient:uuid:3CE4DF44-922B-4B4F-9E0E-28118340C6C7"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2CE48A5-B949-4665-AEA2-11758EADAF68"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7DD5680-2391-4EC5-A99C-AC221DB7CF67"/>
    <pav:previousVersion>urn:domeoserver:annotationset:59A6F148-13BD-4552-BD4D-47BBA15E3627</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A016E782-6083-4FAB-B5CD-6DA0BC2D96ED"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BBE7FC4E-7040-47C6-BAAC-8D9809B16C22"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:84DB5EC5-B980-4493-82E8-5E5D393FE2D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:852C6E07-7D0F-4759-B60B-2F84975DE3EC"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N20b1b98dfab14c858348ad226f68d39a"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA9E42CC-F1E7-4CFD-AED6-F74E23CA07BD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C2FB89B-001A-4C72-9EA0-3B9B45E12DA7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7D1991F-37FC-467F-8870-C6D9F2ED65ED"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B7DC40D-1B3D-4BA0-BA38-41B9DA65EEF3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47F5DF8D-6E93-4BEA-B0A0-65FBF75E4A01"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF9E7431-69B5-4BAE-A020-9DB51109BA3A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE66CAE4-E60C-4BCA-A279-D9DF438AEF11"/>
    <pav:lastSavedOn>2014-06-02 11:54:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-01 20:21:30 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:8272D2B6-0C9A-4ABA-B13E-74867D45B903"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59B9FDA3-7951-46E5-B760-324B32029EC1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:518D89E7-C4E7-42C6-A37E-48F86BA012B4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A6D6B4D-D206-4658-AF73-CF2B2F815A5B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E87AF76A-CA84-48A5-9EAC-16029EFC79C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:49E4005A-EE50-404F-A52D-3249F8464394"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A6302C7-8EF3-460C-B116-7E59FA9BE9DC"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2FB69F2-D2FF-43EF-8D5C-29732917A825"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9F7D401-954A-4681-9DCF-4774DD0355CE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A9F631A-E313-4D6A-A199-3041376B3385">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5577C812-C730-4655-82D1-53CF57390002">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:34C31212-D1DC-40CF-837A-C1FA5DFA4043"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC2F8642-C8A8-4945-9248-35C193593EC6"/>
    <pav:createdOn>2014-06-23 12:09:26 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-23 12:09:26 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7E9ED93-87D0-47BA-B88B-34BF69B8734D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F45B639C-3B87-40DB-8C01-6F3B9616BAE4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A2CD29AE-81FF-4D58-901A-F2401931DC7C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:BCEB5C61-180F-4DF9-A0EA-3FED8818AF99</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D663E74-6CB1-47A0-A481-D85770D95AF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3116814F-1863-4246-8D20-052C3B77E028">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80367309-A4CC-4A89-A00C-C8EA929D52F2">
    <pav:lineageUri>urn:domeoserver:annotation:FB01798D-A999-4067-8ACA-7AD758A919B4</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB280D71-62FB-40FB-94CD-233483856A93"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5266AAA4-C8B8-4FA4-9CB0-2815856888CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD442803-E43A-4E9D-A5C5-BB48D1E4331D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CC9E564-0104-4F47-826B-D8A1DB07DEAF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8447B718-31ED-46AB-8E85-2072C71545DE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-08-10 22:19:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EC426D3-528C-4BEB-81E7-B910EBA3E1B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:10E13CA8-AB04-4965-8986-0EA63CB5BCC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C72F6B71-2159-4110-809B-7357D0414529"/>
    <pav:lastSavedOn>2014-08-10 22:20:02 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DBCFFE9-9574-432A-8429-87D7F9D0F0CF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C2CCBFD-B80D-4BB8-A38C-039E6E9CAE25"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:85364423-8E61-48AC-859C-BFD1E1B50F60"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81499F1E-9A6F-4CB7-A780-7D37A0EDE924"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:346C6C85-1835-4795-8A9D-306529D3828A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECB8B4B2-C490-4136-AE0D-92FF68DEDD4B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FFD9A22-13CF-451C-B6FF-43DB04F9F71A">
    <ao:context rdf:resource="urn:domeoclient:uuid:E803CB09-9D13-4719-B53E-1E801AA58C25"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lastSavedOn>2014-08-10 22:09:21 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A48D75D-6190-4AB9-A732-DF3E0BEA8B37"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11D24A0D-29EE-4624-9F15-0C79D5F74ABC"/>
    <pav:createdOn>2014-08-10 22:09:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A0FAD9F-FD88-4599-80E1-3EF4E8822F08"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDEE7E7A-C23A-4DCD-BED6-BB6915FC115A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:98E92217-DD29-4B26-ACE9-A724F91D498F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF953C5-E175-48F1-A277-32D8647EE8BB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBE98CAE-777E-44FA-8D7A-DB8EA4CA18D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:304FACBA-51ED-4DB1-A0B2-379318BD7A41"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:BB22F4FF-369C-4B8F-A31D-2AC521CBAF6F</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A51DC49-F45F-4CA3-A6F9-06104CA8B14C">
    <rdfs:label>Not necessary</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A96D2815-77CE-4604-9C8F-5A96CA42E025">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D663E74-6CB1-47A0-A481-D85770D95AF2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96F6E308-9D41-4BFF-942D-A5CC552467C9">
    <ao:prefix>DOSAGE AND ADMINISTRATION : Laboratory control ). </ao:prefix>
    <pav:createdOn>2014-06-23 12:01:01 -0400</pav:createdOn>
    <domeo:uuid>96F6E308-9D41-4BFF-942D-A5CC552467C9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96F6E308-9D41-4BFF-942D-A5CC552467C9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A851F571-49BF-4678-9A40-61D2E3DC06A2">
    <ncit:Alleles>CFTR F508del </ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:166E1275-A150-4DA6-9690-B18CDA86FA54">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCFB7B91-25DB-40CF-A05D-7A83778BB16D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ADBCACC3-7EC0-4C1D-9D18-9AC317502BF8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:364E48E3-9581-476A-B552-7EF20E3B5123"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:createdOn>2014-06-01 20:17:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:07689067-83B2-4A59-B4F7-83DFCFA0ED5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B967963-2C76-436B-9F36-EE57DE7CD58D"/>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:63CB3359-94D1-40EE-AF4F-853814B8E2BE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE4EC397-CC34-40DB-8366-77AACB51DEAB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:49ACD5A8-48E7-4C4E-A4B9-DAF372EB24DC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C64AFC4-CF3C-4E4A-97BD-7D4B7BF6C096">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CB87CCD-6C94-40E2-8574-49EE07C75E57">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304628d4c0014629ce3c370001">
    <foafx:name>Will W.</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:middlename></foafx:middlename>
    <foafx:title></foafx:title>
    <foafx:homepage></foafx:homepage>
    <foafx:firstname>William</foafx:firstname>
    <rdfs:label>Will W.</rdfs:label>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:lastname>Wilson</foafx:lastname>
    <foafx:email>wwilson624@gmail.com</foafx:email>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0E35AA6-356F-4054-945A-07801C6240FC">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>HGNC gene symbol confusion as to which</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:802288B4-922E-4898-A87B-459F64B69564"/>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer</ao:exact>
    <pav:createdOn>2014-06-01 18:56:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A347C07-F901-4339-8495-C605FC5F87B6">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEB40654-A080-4760-9A83-B99D16F9E0F2">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35666F56-D1B1-497D-AB6C-BD5EFD747D6A">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22B6B7B7-1C06-4D87-9D94-878BABBA422C">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E87AF76A-CA84-48A5-9EAC-16029EFC79C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-02 11:50:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-02 11:50:17 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:D37E1623-1515-4F6A-93D4-F3BD2BBC1DE1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:040E1451-9494-4650-9EE0-23B7302B057A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF3691C6-184F-4B0B-A35B-2A7D10DECD85"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C3FDE415-0F58-43EB-AACA-E9FBA23086DF</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:04514E5A-CC45-47DE-9281-2FBD57AC110F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3ED74D87-17C8-4371-908E-0ED43A8E305C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DD80216-E6DB-48BD-A9C1-D37C6D156E4F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:630171C7-516F-4D9F-AFE2-922953BD73B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF247ADE-CEC1-4294-951B-E346EEFCF880"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2088FA5-4C4B-4269-BE84-0CBECDFB6D49"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07BDCF78-FF4E-4E7B-B35D-B720E7D377B6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3ED74D87-17C8-4371-908E-0ED43A8E305C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>3A4</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E80F8715-EB61-449E-A924-4D82E72F059E">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F53CD0AA-C7AA-4D7B-BF7A-D18481B4C9C7">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F23D9B73-FB11-4CF4-8608-428C04B0402E">
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D2D084F-6A5B-4E87-9B36-958F2E5BA705">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FA9FE6F-9E01-47C4-8CFE-9C9218690AF5">
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.6,7</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-23 11:57:50 -0400</pav:createdOn>
    <domeo:uuid>0FA9FE6F-9E01-47C4-8CFE-9C9218690AF5</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0FA9FE6F-9E01-47C4-8CFE-9C9218690AF5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:964268AF-4FE2-48DB-9262-846359807A55">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91B3B532-B1D4-4608-B8A6-50E42526D8E0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE7DDEB4-B524-42A9-A555-BF280A81D168">
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D075A98A-6E8D-4058-8053-C50ED33E10AC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC92C403-A358-4166-9C88-260062DEA659">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:097C6676-BD3C-476D-AEF9-38CD5B1039FE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69C1542B-D7E7-491A-A589-9E0649208AE9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:43:17 -0400</pav:createdOn>
    <ao:exact> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix> In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4999A1DA-C288-46D8-A62C-B991C9A4B2F7">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45F7DA71-DCBA-4667-AD78-F695417EFD56">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29724897-7FCC-4FE3-8892-8BA2C20F9F46">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>pd impact implication or clear cut?
no specific test recomendation however indicates there is one
estrogen and progesterone are in many products (does this warrent cocomitatnt med concern?

biomarker positive and unknown + 2 annotations?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:945AB3F9-D117-4A09-A4D4-85964D29ACAC">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9E692FA-1CD1-45DF-863F-A8ED78A0B690">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
    <pav:createdOn>2014-06-01 20:50:40 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7E9ED93-87D0-47BA-B88B-34BF69B8734D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-02 11:47:03 -0400</pav:createdOn>
    <ao:prefix>nistered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3"/>
    <domeo:uuid>0D3B9099-D4D4-4D0D-BB45-DACEAE2FC2E3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7E05FB0-37B2-4601-A2FF-95A3B9FFFB28">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Should this be broken up into multiple annotations or left as one with ambiguity? </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E48ED1B-3777-4298-91AB-D77AE62BB35B">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6AF5971-80AE-4A6C-A511-F82D7494B773">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75643664-2DC3-4767-9EE6-7CCAA29DA216">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, </ao:prefix>
    <domeo:uuid>75643664-2DC3-4767-9EE6-7CCAA29DA216</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75643664-2DC3-4767-9EE6-7CCAA29DA216"/>
    <pav:createdOn>2014-08-09 12:43:16 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BF50FFA-DA12-46AF-BBED-6EB8317EE709">
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB954038-FFFC-4316-BEAD-EC8BDC87C07D">
    <ao:exact>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:exact>
    <ao:suffix> (Table 1).2</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB954038-FFFC-4316-BEAD-EC8BDC87C07D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 11:44:00 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>EB954038-FFFC-4316-BEAD-EC8BDC87C07D</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99F398CF-DA8E-4ACF-A452-BAC543EA248C">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7D1991F-37FC-467F-8870-C6D9F2ED65ED">
    <ao:body rdf:resource="urn:linkedspls:uuid:836A37A7-4D0B-4AFA-8D09-94C3EA62FCE1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD1D3598-88CE-46BB-AE4F-E410622B3983"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7CF9EE50-16A4-4EA2-B576-E055C8795A9D</pav:lineageUri>
    <pav:createdOn>2014-06-01 21:05:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:939C0307-55CE-4736-AA11-38175F4EE10A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32DCFD4A-6714-434C-AA86-D67DC3A89BA4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A14343D-5DC1-4861-9651-2DCE58B59689">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EDAF04C-683D-423D-82D0-BBF1C483F6D2">
    <pav:createdOn>2014-08-10 21:58:26 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A1E5365-AE78-48D0-A03B-32D33C4DB5DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9E692FA-1CD1-45DF-863F-A8ED78A0B690"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-08-10 21:58:32 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:882C3EAB-2393-4BC7-BE0C-50C6F50EED5C</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CD56515-EE89-4871-8989-575D25CD76D6"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:211BDD97-B2B1-4815-8C1F-EB8664060C81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8DD07D2-59CF-4D79-B610-9E30AFBB09EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC1949CD-5C5D-4C24-B2E1-52904E49993D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE05AC28-7AC6-4765-98AB-EFB89FE08808"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C42C9A0-2255-41A3-B346-EC49AA4FB231"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:76DCD01C-EACD-4FE2-B931-F749126BAA57"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC8F5C14-C49E-4393-A15D-899E694863B8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7D6DCFB-F392-4717-B6BE-F959A2CCED80"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:310FFE09-A6AC-4320-ABE2-C36D42DFD8E9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2478321C-4685-406A-BBDC-5CC5CE480557">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94D136B7-11C7-4F96-99E9-8788AB0C1DB6">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:704A2F41-D55D-43C7-8C57-73DA2EDA6EF6">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Imatinib</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2B19285-CDA5-4F48-BD66-9F40377683C6">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7710276-C3CF-4F0D-8858-38F6F53477A3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-08-10 22:34:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:556DBB2A-7A01-4225-9193-57FAA5081013"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D42F9F66-D37B-4507-91FA-136AEA8DA642"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E7D9F2D-657A-4D1C-A6F7-50F65349E4B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD496EA6-ABF1-4F0C-A3F2-C1D79B30F4AF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:A00C0B39-57C5-4728-9A77-DB517755C810</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E69F2A87-8558-415F-80F8-2D53B0FCB632"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF07AC73-5059-43CA-A262-B59652BEDC03"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8CE207E-13B7-4302-ADFF-08E5EA02E0FC"/>
    <pav:createdOn>2014-08-10 22:34:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBD0203C-5085-46C8-9967-6925BBD433DA">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC2F8642-C8A8-4945-9248-35C193593EC6">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549">
    <ao:suffix>[see Clinical Studies (14.4, </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:20:14 -0400</pav:createdOn>
    <domeo:uuid>603D28B5-7467-45FC-88C4-58C305EE9549</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:603D28B5-7467-45FC-88C4-58C305EE9549"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A25A28C-E3A8-4E68-AE36-EFD658F4D76F">
    <ao:body rdf:resource="urn:linkedspls:uuid:8CB87CCD-6C94-40E2-8574-49EE07C75E57"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2412BBA1-8042-4E16-BB46-9010B035CC06"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC560B3F-80E8-45DF-8C22-E3764D8A78E3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:7852C3C0-B9AF-40A3-9E8D-CCC1804296A0</pav:previousVersion>
    <pav:createdOn>2014-06-01 20:25:43 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2643A08-C95E-48C6-930F-8CE9B9775384"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0A9BA42-4FB0-46B6-BAF5-795971CA1806"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:29724897-7FCC-4FE3-8892-8BA2C20F9F46"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:928318F4-75B6-4942-841F-EEAC3724CEC6"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:24950A77-AA81-4C28-864F-AEDA923C8518"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F22F3EF-3DEC-46A7-8991-5011D63F1093"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:836CABF8-8E8E-4739-8AF2-34CCA31278ED"/>
    <pav:lastSavedOn>2014-06-01 20:28:23 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9704EE13-B090-4512-A4E3-F8DDD0AAB50F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <ao:exact>Strong CYP3A4 Inducers: Do not administer for at least 2 weeks prior to initiation of irinotecan therapy. (7.2)\nStrong CYP3A4 Inhibitors: Discontinue at least 1 week prior to starting irinotecan therapy and do not use during irinotecan therapy.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9704EE13-B090-4512-A4E3-F8DDD0AAB50F"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>9704EE13-B090-4512-A4E3-F8DDD0AAB50F</domeo:uuid>
    <pav:createdOn>2014-08-10 21:28:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-02 11:30:34 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease.\nAmong women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).\nBenefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS). The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>F40AD074-2E47-4331-866A-6D66E6A1356B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F40AD074-2E47-4331-866A-6D66E6A1356B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD29F999-6BE6-4296-85E2-66DAA123889B">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E85BAB5-4509-4E83-8CA7-75A9A691FC69">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-08-10 23:13:20 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:AACB1609-9D80-4D63-9834-1F4B71E77FD1</pav:previousVersion>
    <pav:createdOn>2014-08-10 23:13:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CEA8726-35F7-4552-BB24-EE3069597FDB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4101E819-5264-4B71-9EB8-F0A70B83A01B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BF50FFA-DA12-46AF-BBED-6EB8317EE709"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4538143F-DE97-4802-B4E3-0B94CB8B7822"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:973A257C-A669-4CFF-AA07-27EA5C59A05E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A479CBD-F4BF-4914-A061-B99A738ED0ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FAC52E6-4633-4679-A786-5EDE285F0789"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91383B95-AE29-4D4E-82B3-2565E0F7C5AD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6656052D-E3F6-4660-8905-DFB8B98C0CC7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7958A3F8-2010-4802-8B0D-1AEC97EE0741">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7D6DCFB-F392-4717-B6BE-F959A2CCED80">
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8870565E-1A59-41E3-9AAE-8EE2DC9C2A90">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2662590-EBA5-4EF7-BFB4-8040243ED1B3">
    <pav:lastSavedOn>2014-08-09 21:51:09 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:60B4A42A-5A0B-4AAB-B5E9-D49C6FDBA62B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:60AD1445-5032-42EF-9218-A28C9C349C0A</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C089F1E-09E8-422E-9CBE-F7C1E62F41E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F71F1BDE-257C-47CF-B351-3DA8C736B140"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-09 21:50:49 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FEB6CAC-68D2-4C9C-972E-4494AE232800"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:63273F2D-06DF-4FCA-8DD7-BC0DAB237B66"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA0A4DC4-408C-4EEC-A396-79968EDA93F6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9506DD30-BB96-44C5-906D-EA722A1488D1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9248F74-5362-4BCF-AE17-0776F97727F8">
    <pav:createdOn>2014-06-23 12:06:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF284ED1-7B3E-4A3C-9CD1-8AEBB065A0F7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35F14E43-E525-45CA-BCC8-C962B209578C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BEB40654-A080-4760-9A83-B99D16F9E0F2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE0888E1-BFCD-4735-8AE9-6C63EC65E364"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17C174F1-29A3-409B-A824-DEB39FFC2604"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2BC2D8C9-E400-4714-A9F8-522CD445CB23"/>
    <pav:lastSavedOn>2014-06-23 12:06:14 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D017E663-B46B-4580-B8C0-29ACBDCAB4AE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C4D6D414-7EDE-4B56-A45C-30F5A0023D11</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB8775C1-7B43-429B-AF1D-3BB7F8D10798">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CFTR G551D</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12E4CAC0-7F66-468F-8C2A-B6F55FD2596A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>how many annotations
dosing?
homozygous vs heterozygous?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6EE754B-3ACF-4D28-82B0-173F818815F2">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77D0D8B2-83A4-43B1-82A7-ABE5233A32EE"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix></ao:prefix>
    <pav:createdOn>2014-06-01 21:05:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>\nif tamoxifen citrate tablets lowers the chance of getting breast cancer in women who have abnormal breast cancer genes (BRCA1 and BRCA2)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8350EA7-C8A2-44AB-BE69-6B1844DC8076">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3219E3B4-644F-4DCE-8741-7846947834CD">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD701664-00FA-430B-8ED4-68328F2A3736">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD701664-00FA-430B-8ED4-68328F2A3736"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:exact>Coadministration of atazanavir sulfate, a CYP3A4 and UGT1A1 inhibitor has the potential to increase systemic exposure to SN-38, the active metabolite of irinotecan. Physicians should take this into consideration when co-administering these drugs.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BD701664-00FA-430B-8ED4-68328F2A3736</domeo:uuid>
    <pav:createdOn>2014-08-10 22:10:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8840FB3B-47B3-4958-864C-619B7A4F6927">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09D2862B-D8FB-4E09-9821-80C159195148">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09D2862B-D8FB-4E09-9821-80C159195148"/>
    <ao:exact>In a prospective study (n=250) to investigate the role of UGT1A1*28 polymorphism in the development of toxicity in patients treated with CAMPTOSAR (180 mg/m2) in combination with infusional 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%. Grade 4 neutropenia was observed in 1.8% of patients homozygous for the wild-type allele.</ao:exact>
    <ao:prefix>once-every-3-weeks), the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%.  No grade 4 neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype). </ao:prefix>
    <pav:createdOn>2014-08-10 21:56:56 -0400</pav:createdOn>
    <domeo:uuid>09D2862B-D8FB-4E09-9821-80C159195148</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36F5E628-9E69-4B85-BE35-CCE2A0B36037">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE74ECF6-B96D-4299-9C46-7591BA467AB4">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AA7F636-6F42-4B80-841F-F2B140D5A4DA">
    <poc:Comment>ambiguous when taken  a whole this label. previous statement with n=81 indicates no impact, whereas this says nothing is known.

HGNC Biomarker need to be changed</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF4DFBD8-3AE3-44AE-93A9-B7C47ED50540">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FFD0391-8E1C-417F-B431-7442EDC03CC4">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F18EABFA-DE53-4697-A79C-CE2728D2CEAF">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Not necessary</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02A7F7C9-1174-48A2-9349-4C1F7C9119FD">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9ACFA9D-1F43-40DC-804F-548CA84C099D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A1366B4-29EB-412A-B68B-B95F336BAF7A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90E5A53B-2462-4558-8CE2-4A7DFF65554A">
    <ao:body rdf:resource="urn:linkedspls:uuid:3672CD89-8481-45DE-B9C2-D28EBE22060E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61DB2955-E3A3-4920-BFAF-9CC063073BD3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F54608AB-77EF-415E-A3DD-3DD07F40A174"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FBA0754-1C09-46E9-8403-905ED4826F03"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-23 11:47:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5CA7EB8-7EEC-4191-AC78-3FCC3B133397"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB954038-FFFC-4316-BEAD-EC8BDC87C07D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:445CC80C-C238-4D86-9748-F26C4AD69228"/>
    <pav:previousVersion>urn:domeoclient:uuid:A7AF9F89-DE14-400E-B4F3-8C885F77B479</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <pav:createdOn>2014-06-23 11:44:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AA0A022-FEC0-431B-83B2-D6933B368C60"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C8277B5-2CEA-46C3-AB1E-07D587682276"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59B9FDA3-7951-46E5-B760-324B32029EC1">
    <pav:createdOn>2014-06-01 20:50:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6EE754B-3ACF-4D28-82B0-173F818815F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B38E1606-AC23-4903-9AB5-50032A302E19"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:51D8AD88-84BD-499D-89B1-5A13D094E89B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:01C992FE-311C-4E00-AA6C-D5D9E37D6718"/>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E3BC098-863B-4FD1-9E5F-F4C244D690CD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D33A037-01E3-4544-9149-0E57600DD51C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:529A0D57-6754-4EFB-BE67-B5338A1E859F">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34C31212-D1DC-40CF-837A-C1FA5DFA4043">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2412BBA1-8042-4E16-BB46-9010B035CC06">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD5AFBC9-5CBF-4536-B0E9-B65EF81A8338">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50DC0725-A112-4C63-82E0-3AE9A8BFD396">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F10EFFF-945F-4AEB-92CC-57E417F7F69A">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA1A5436-6353-49E0-B158-D24D32105570">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:76</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>BCR/ABL1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36DD3963-A8D6-4D07-AC3E-1DC7BD45A6C2">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:156F9063-0388-4A4D-8A0C-941D0AA70CD2">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ALK</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:427</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55224E52-1CF2-4A49-B39E-56ECA1F81AAD">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8C4145B-541F-405A-97D9-77D5041238F0">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:624952BE-02FA-4DBB-A8F8-7C324A7D27AE">
    <poc:Comment>BRCA1, BRCA2 need to be added to HGNC Gene Symbol selection</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A8F5C12-2D71-4D44-8E06-0292198A80FE">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Imatinib</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4A4214A-FDFF-4CBD-87E9-A1016E1FC8C8"/>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2014-06-01 18:43:11 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87F8C3BB-7E20-4F92-BC4B-966D4B818F54">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:273F41C8-6FEB-478E-9B7B-89E3D99894F0">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdfs:label>CFTR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:348FD9AF-1DBC-47C5-ACFF-93B56E3FA1ED">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9B2E784-E7B7-4BE7-9644-C8BAC52301DD">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CA122B4-F5F4-47B5-B5A6-4EE8F03DE5BA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A6D6B4D-D206-4658-AF73-CF2B2F815A5B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB147F25-1B88-4069-9256-A953968F81BF"/>
    <pav:lineageUri>urn:domeoserver:annotation:5AEDF9CC-43ED-4710-B590-4D225771E8D1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 21:05:20 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B0EBE3D-E880-49F6-AED2-BCC056A7B6BA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:801E4361-583C-4097-9F47-7910FDF70718"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:182124B1-5996-466F-858E-FC532C12BD72"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B64B9D8-3BE7-46A5-99E8-51142C33754A"/>
    <pav:createdOn>2014-06-01 20:57:33 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4756A35-9B6E-41CC-BFA7-5E427BFBE0A7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B513A5-D56D-4DF6-A372-20CB0B78A444"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648">
    <ao:exact>Tamoxifen reduced the plasma concentration of letrozole by 37% when these drugs were coadministered. Rifampin, a cytochrome P-450 3A4 inducer reduced tamoxifen AUC and Cmax by 86% and 55%, respectively.</ao:exact>
    <ao:suffix> Aminoglutethimide reduces tamoxifen and N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-02 11:23:15 -0400</pav:createdOn>
    <domeo:uuid>D2F60DE8-DB29-4E1E-870B-8EBBD05CD648</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5999E193-A258-4C6E-8E0E-1460FC80FFD4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Drug selection question </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E8D4706-2C30-430D-876C-02FC03E707F1">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BEF81E9-82FD-450A-8BDF-59AFEFE9B8EB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4538143F-DE97-4802-B4E3-0B94CB8B7822">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2862160E-0C90-45F3-A1C3-CD3359CC6B47">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DBD21EF-4879-4D35-803C-84ED3C4FEEDC">
    <poc:MedicalCondition>neutropenia </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2ED739B4-0C5F-4523-B4E9-9392184D80A5">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21D08972-D7E1-4EFA-A34A-DDE979260133">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9ABCB3C0-F126-474E-8961-241E8212DB5F">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB87CE99-B099-4809-88F7-56477D6C0E03">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Ancestry
Two annotations due to CYP2C9 and VKORC1 mentioning</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1591CEC1-2E0C-4312-B4F1-C0D0F14BB0BC">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAA6B2E8-AB2E-48A6-9E3D-440B18DADA76">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a35323a88fe4ed78858a67fb140f8f5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26CDE94B-D998-462C-9885-E20EB5CB5EBA">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DD7301F-B239-42ED-8AC3-535CF0C77261">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal women
early breast cancer
breast cancer
cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB7F5CE5-2A4D-469D-82B4-26C64B9D23AD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5ABEDBB-1537-4826-8A67-D1D682B8E8B4">
    <dct:description>A required test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C3AC9B3-D601-4136-A811-7C38BDF19C43">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC00101D-0828-425E-8C39-55A240DC2F1E">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF4D4B11-F8EC-4658-B8D0-687F5D34C9E3">
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
    <rdfs:label>Ph Chromosome</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90D9A756-BB32-44FF-A32B-723CE7EA83C4">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Ph Chromosome</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4756A35-9B6E-41CC-BFA7-5E427BFBE0A7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33E8EA8F-B9E5-40E3-8665-37032B0ED7C5">
    <pav:createdOn>2014-08-09 21:53:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>33E8EA8F-B9E5-40E3-8665-37032B0ED7C5</domeo:uuid>
    <ao:exact>Gleevec increased the mean Cmax and AUC of metoprolol by approximately 23% suggesting that Gleevec has a weak inhibitory effect on CYP2D6-mediated metabolism. No dose adjustment is necessary, however, caution is recommended when administering Gleevec with CYP2D6 substrates that have a narrow therapeutic window.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33E8EA8F-B9E5-40E3-8665-37032B0ED7C5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D58D76C-8E3C-4BA5-BAF3-61389559D329">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22D1D12A-D376-4A58-BE50-04FA3F26EAA7">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DCDF13F-D4DF-457B-8941-06DC89D9BDEE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D7A889E-54B0-4493-BC62-5D2D79894A46">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-01 20:12:29 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5CD1AE27-AFD2-4F5F-BF55-2EE63DF53514"/>
    <ao:suffix> (1.1)Extended adjuvant treatm</ao:suffix>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for:\nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04539A04-F082-4C33-9B14-C8B5A2B0E0B5">
    <sio:SIO_000111>(34071-1) WARNINGS</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34071-1) WARNINGS</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:546478F7-7C88-4C9A-B137-679B6C0B0C4A">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A95CCA4-583E-427C-978E-922968ADA282">
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5C48B4D-07D6-4422-8681-560601367419"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <pav:createdOn>2014-06-23 11:39:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:971C0313-9F4E-49B3-8319-EE5DC4F29891"/>
    <pav:lastSavedOn>2014-06-23 11:39:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC8FB036-D968-47D5-9988-95AB8EF17F4A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D87F1F2-02FF-47FB-BE00-E115E4BE49D6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:836049B1-A0FB-436F-9DBB-6E23FF2B22B3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D111BF54-7F6A-4982-BA99-8FBD11522EEE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1155018E-438A-45A3-91CB-3ACEAB3A5582"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5F0D7FB-E816-4314-B450-214BD51BDA11">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B30E27C7-9FC2-49F9-8322-0F737014ACC2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00E533CC-9E0A-4875-87A4-43C3C4D56B23">
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N25ca8a1f4a804e6781ff2a3700bf39d8">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B2E9778-C8C5-442E-9DD2-1DB882A461AB">
    <ao:exact>KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B2E9778-C8C5-442E-9DD2-1DB882A461AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7B2E9778-C8C5-442E-9DD2-1DB882A461AB</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Limitations of UseKALYDECO is </ao:suffix>
    <pav:createdOn>2014-08-10 23:06:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F653188-E3F2-4B37-B6D6-E7EA7F7FE727">
    <ao:body rdf:resource="urn:linkedspls:uuid:77373F3B-8EA0-4F35-A16C-9D6271129C95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:245F37A5-3BE1-443A-A92C-4A86E8464BE2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:52A069C8-DE95-46AC-AD2C-ED7E1E47462D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3116814F-1863-4246-8D20-052C3B77E028"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5077EC81-E9B2-4F29-AE51-2A51E75DCBE2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D14C1107-3ED0-4351-923C-D114C4559F07</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A373252B-CF9E-478E-8ECD-B451ED7FC5DB"/>
    <pav:lastSavedOn>2014-08-09 20:21:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF064F23-7A86-413E-8EA7-CEBFFF5889FF"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD417187-DEC1-41B4-8747-B7CCC73A8AD1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:4E4E330E-AF5C-4C83-A581-FB716F532136</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:E69D5D39-08C2-4F6A-82D2-9BB1F2BAE7B2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:59FA88B5-7EA5-4974-9C1C-29E4CE65FE56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2EF7F52-F1D9-47EF-A074-4194D2550A74"/>
    <pav:createdOn>2014-08-09 20:07:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C973E9B-5F63-41AB-8FD5-CF3A9FCA95DF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact> The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <pav:createdOn>2014-06-23 12:08:58 -0400</pav:createdOn>
    <ao:suffix>             </ao:suffix>
    <domeo:uuid>2C973E9B-5F63-41AB-8FD5-CF3A9FCA95DF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C973E9B-5F63-41AB-8FD5-CF3A9FCA95DF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known.</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E93E67E-7C76-44BE-AFE1-D5AE75C92344">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E803CB09-9D13-4719-B53E-1E801AA58C25">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-10 22:09:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E803CB09-9D13-4719-B53E-1E801AA58C25"/>
    <ao:exact>Ketoconazole is a strong inhibitor of CYP3A4 enzymes. Patients receiving concomitant ketoconazole have increased exposure to irinotecan and its active metabolite SN-38. Patients should discontinue ketoconazole at least 1 week prior to starting irinotecan therapy and ketoconazole is contraindicated during irinotecan therapy.</ao:exact>
    <domeo:uuid>E803CB09-9D13-4719-B53E-1E801AA58C25</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C089F1E-09E8-422E-9CBE-F7C1E62F41E7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Imatinib</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39C5C1E8-D80E-4CBB-99A0-4AB410862B09">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in absorption of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#absorption-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Absorption Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A133F4C2-702C-4A40-BF70-F7A8C2059EDE">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6159ACE8-3CEC-4C84-88D5-F682557F209F">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88EE3C83-F59F-43AE-B4CD-71A4C44F1E33">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBE7FC4E-7040-47C6-BAAC-8D9809B16C22">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:44B83470-7A63-4402-A977-48C1847BDF4D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:1AC91D44-43AB-461A-BBAE-2DB0CE3D63A9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3563965-B210-42C0-9FF0-A3486F2240E1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:39C5C1E8-D80E-4CBB-99A0-4AB410862B09"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:10DE53A3-0606-4583-BA2D-25D07EA38D58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6A60543-E70E-4659-BE33-475B15815CF3"/>
    <pav:createdOn>2014-06-02 11:23:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-02 11:23:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA82B2B8-D75E-48D2-805D-7373ECD081EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4BA538D-61A7-4EAD-8570-A3A806489044"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2F60DE8-DB29-4E1E-870B-8EBBD05CD648"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8ED8D02-7F93-41B5-908B-D5A8A907DF30"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BEA2D87-30DC-468E-A64B-7DD7CE2A76D7">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B590989-98A9-4FC3-9F06-44D7192C82FD">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C49E36DE-5ECE-4AE4-8054-4C31FF132938">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECF411C7-5E58-4EB7-ABF0-33EEE5C22D04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>How many annotations
I count 3 for positive, poor, and unknown.
</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3353B039-964D-46C9-8693-7B6C85A1C742">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00321</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Amitriptyline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACED33D5-A0D0-4B2F-90C6-8FC7E39EED97">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:994E0CF7-0D24-46F2-9307-D7615779EC81">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF878A63-A581-4A98-90E1-091C1136F553">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>How many different annotations</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC735722-FA0F-47F5-A97D-9F2FE406D9C2">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF914CBA-27EE-4C33-A929-F5D51EED1623">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7D91160-12DF-4885-A5EB-9FF75CE648B9">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01C992FE-311C-4E00-AA6C-D5D9E37D6718">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9506DD30-BB96-44C5-906D-EA722A1488D1">
    <rdfs:label>ALK</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:427</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C243EC9-2225-4772-9FAC-3D93C17E4CAF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:246FC7F0-0FDD-4242-9C08-71340FAEBED2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:370AB788-B410-4EF4-A015-06EEAC3F3446</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DD7301F-B239-42ED-8AC3-535CF0C77261"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5999E193-A258-4C6E-8E0E-1460FC80FFD4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:32E1E9EA-32B8-460F-B557-2CA8E3B4CC01"/>
    <pav:createdOn>2014-06-01 20:15:14 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:71923767-C4E7-42DE-84F8-01605D56F151"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:76EA7D30-E3C4-4197-A7B4-293995F38E7C"/>
    <pav:lastSavedOn>2014-06-01 20:20:47 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF079F40-0025-456F-8288-81DF3604F1DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B667F421-8E8F-44D2-9A57-4CC1AEDC2893"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69D70A19-BD83-4C1B-BE23-D5B62C7C1389"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC00101D-0828-425E-8C39-55A240DC2F1E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD241C8A-F9B8-4F6B-A5B8-FCE8ADC1A98D">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4607D130-54A4-475F-8D06-53BC41F21B1B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81B49A95-D438-4609-8F7C-C3A0DFE821FC">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>no test rec
dose rec???
no pk impact stated or pd impact, strange
</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15A3CCCF-DDCF-4E73-A457-2440F73F8650">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:716AA449-886E-4EEB-BA11-F9A08EB6C6C7">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6444E3DF-9538-405D-9B09-616E34C4B756">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADBCACC3-7EC0-4C1D-9D18-9AC317502BF8">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46F6BA9D-79BA-48A7-91D5-BBFC46775697">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34070-3) CONTRAINDICATIONS</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34070-3) CONTRAINDICATIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5CA7EB8-7EEC-4191-AC78-3FCC3B133397">
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F0338DC-F37D-4C91-A293-A18AE7C2CEFE">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-06-01 19:37:29 -0400</pav:createdOn>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F0338DC-F37D-4C91-A293-A18AE7C2CEFE"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4F0338DC-F37D-4C91-A293-A18AE7C2CEFE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93EB68A8-43E3-449A-94B3-3B9A4ABF34F8">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdfs:label>CFTR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:605637B9-912E-4844-8BE8-343B87CE069B">
    <ao:body rdf:resource="urn:linkedspls:uuid:02A7F7C9-1174-48A2-9349-4C1F7C9119FD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:701B5BEA-B33E-4E29-93F4-6347E02054DC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:12F85D8C-0C64-4074-AD70-0023DF39FE0C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87F8C3BB-7E20-4F92-BC4B-966D4B818F54"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D3A2870-2868-47BB-9FC9-F685CA0F2EE6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:57EFC962-653B-4E28-8298-89EFD1EDAA95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F96E312-FA4B-452F-9AD1-A471C984DE2C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:lastSavedOn>2014-08-10 21:59:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C93E6EF6-A816-4813-938D-C1FE6702DC55"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A31D2DD5-7467-4C65-B296-B64ECEED7352</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:31EE354A-10AC-4F7D-86B9-07D649455403"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:12153C41-67BB-4F0C-86FF-7E4F110181F5"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-08-10 21:59:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B49A8982-2AC0-4EB5-B28A-FC33CF719F1A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A016E782-6083-4FAB-B5CD-6DA0BC2D96ED">
    <ao:body rdf:resource="urn:linkedspls:uuid:3219E3B4-644F-4DCE-8741-7846947834CD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8350EA7-C8A2-44AB-BE69-6B1844DC8076"/>
    <pav:lastSavedOn>2014-06-01 20:50:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9631DAFD-657D-4B15-B45C-6749370AB9DC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A255621A-A331-414A-A131-3C653D2592AE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:468FE543-AD1E-48C2-AEC2-929DA27DC15F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:E52D7AF5-8AC1-400C-B035-9C0F0E0306F6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:23B5DEBF-032B-44AD-86B6-0A5665A87474"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-01 20:29:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2B19285-CDA5-4F48-BD66-9F40377683C6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:53F71014-8A27-4415-B21D-AFF704D17012"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EE51A830-95AE-4160-ADAF-F16C7E7CF094</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDA25E4F-5AD6-49AC-BFDC-FB737EF18E43"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FC2FDC3-15E8-4CB3-8CA4-01B7647070B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79355B65-05D6-44AA-A39B-F1922D63984F">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>UGT1A1 6/6, UGT1A1 6/7, UGT1A1 7/7 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:245F37A5-3BE1-443A-A92C-4A86E8464BE2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5F34B00-9314-4FDD-8D6B-4F611AB89216">
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D639719-720F-4CF6-8552-F48A8BA06D92">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4340CA7-5C58-47D6-B8CD-28A2E3CB9F9F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D4340CA7-5C58-47D6-B8CD-28A2E3CB9F9F</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4340CA7-5C58-47D6-B8CD-28A2E3CB9F9F"/>
    <ao:exact>Anticonvulsants and other strong inducers: Exposure to irinotecan and its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine. The appropriate starting dose for patients taking these anticonvulsants or other strong inducers such as rifampin and rifabutin has not been defined. Consideration should be given to substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-10 22:05:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9a260759f1024a099ae0060cb5ce17d8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B82BB5C-552F-4359-8117-65E2C21FB4AC">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3847D7EB-4227-42C4-B28F-B22DA27F48C3">
    <pav:previousVersion>urn:domeoserver:annotationset:E92269C0-B04C-4CC3-84BF-BBA54FA3446C</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D639719-720F-4CF6-8552-F48A8BA06D92"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB129B84-A824-4B8C-BF70-9759A68C71B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80C6E754-D72B-4024-8D61-FEF86F5C6A3E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2478321C-4685-406A-BBDC-5CC5CE480557"/>
    <pav:lastSavedOn>2014-08-10 23:21:01 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-10 23:20:55 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3EDBAB4E-9BCC-40E2-84C7-354A385E17B9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:93EB68A8-43E3-449A-94B3-3B9A4ABF34F8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D14ACD4-0847-4931-973E-9006DB7D24A1"/>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:063BE245-52EF-45FC-8786-26709F5717B6">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55EEFAEE-05B7-4F9A-9ACA-C116E05AD138">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Irinotecan</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB6B01C8-0B4A-4A1B-96FB-1F1C5B4D4BAB">
    <poc:MedicalCondition>breast cancer, postmenopausal</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBEB0ACB-D1CB-409F-8826-3D87E728DE4C">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C47931C3-FF92-40EE-B9BF-22ED1590EB9D">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>Ph Chromosome</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99C32C61-7BC3-4B93-872A-CCDF4689D717">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F45B639C-3B87-40DB-8C01-6F3B9616BAE4">
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23BD8DF3-C5D7-4B70-BACE-FD2C81662D9C">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Ancestry a catch all for African, Caucasians, Asian...etc?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B858186-07FF-44BE-863D-05D40DD39D4F">
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0873D062-8063-4C54-9319-262761698F98">
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F22F3EF-3DEC-46A7-8991-5011D63F1093">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C478D95-94FE-474B-B9ED-AA77113212FD">
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC309F61-F4BA-465B-BAB9-9C78A9178FAE">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4693793C-A4BA-4B78-8FEF-0E9B1A3DCA6D">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DD2DB5A-AEF5-4D7C-9D40-0EDE5D80DBF8">
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD16BE80-5B8E-43B8-B9F5-17051DEF6533">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Clinical trial indicated = available evidence?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:669C65A2-428A-40D8-AB6B-42D149C8F608">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36D4BB19-CD41-40DB-A590-DF3ACE4A001F">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB66CB97-AE1B-44B7-9572-EEEE1FB82DB9">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7054B823-EEB9-4382-A2A5-3B431182A090">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:043A8FED-C2FF-4047-BA84-C4896E5062DA">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:056DFCFD-7A3D-456D-BD1C-B5E0D7699D95">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61365053-2F51-497B-9187-D1A7F6A291ED">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF508BF5-0707-4BB5-9669-06BE9AD4A04C">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8A250D1-1146-42CD-8A54-D943B9E00644">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E73C31F-DD90-40FB-A350-824AB17D8D15">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6A60543-E70E-4659-BE33-475B15815CF3">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34073-7) DRUG INTERACTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34073-7) DRUG INTERACTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C35CE08B-2D0A-445E-8FF3-98CB7A953446">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer, </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD442803-E43A-4E9D-A5C5-BB48D1E4331D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:304FACBA-51ED-4DB1-A0B2-379318BD7A41">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N683bb8d746494ef49081f889d72ec125">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6ACE7D97-748C-4A09-A70C-305797C988E5">
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0A9BA42-4FB0-46B6-BAF5-795971CA1806">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DB028A4-A674-45A7-9DF4-00F4939D4E28">
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B0F98E5-9941-4185-80B8-29A789540691">
    <ao:exact>Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B0F98E5-9941-4185-80B8-29A789540691"/>
    <ao:prefix>Total188</ao:prefix>
    <domeo:uuid>8B0F98E5-9941-4185-80B8-29A789540691</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-23 11:47:09 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F25644F-CDA4-4278-8179-A60F89B2CC89">
    <domeo:uuid>2F25644F-CDA4-4278-8179-A60F89B2CC89</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:suffix>
    <ao:prefix>ing 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-23 11:51:03 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F25644F-CDA4-4278-8179-A60F89B2CC89"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51821848-7A49-40DF-B961-F06F99704966">
    <pav:createdOn>2014-06-23 11:54:29 -0400</pav:createdOn>
    <ao:exact>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.4</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:51821848-7A49-40DF-B961-F06F99704966"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>51821848-7A49-40DF-B961-F06F99704966</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E69F2A87-8558-415F-80F8-2D53B0FCB632">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE0FFD2D-D369-494B-833F-337DB6A99036">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-09 21:51:09 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B83771A3-17DB-4346-B9D3-E8DEA72C9BCB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D22780EB-1BE5-4449-9BEE-E2BEDF0CDE78</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:06FA4BBD-EBB3-42A6-8835-4B46EC74B8FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C47931C3-FF92-40EE-B9BF-22ED1590EB9D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdOn>2014-08-09 20:58:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DD7DD05-2925-4F7F-B8C0-A4A75F188272"/>
    <pav:previousVersion>urn:domeoserver:annotationset:60AD1445-5032-42EF-9218-A28C9C349C0A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EA0A0955-5E5C-4000-B99A-E4C131DC6D71</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:15A3CCCF-DDCF-4E73-A457-2440F73F8650"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9704426-CE3F-49D8-B1BA-14F8EDD6988F">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBF80EB5-5867-4378-8F30-8764383B5F42">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45BA0CBA-7217-4D45-8C6B-F3247F353A9F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F58EE64-7DC9-495A-92B7-AF8B1CD1EC2E">
    <poc:MedicalCondition>tonsillectomy 
adenoidectomy 
death
respiratory depression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4B2801D-AD10-4FC0-A504-C6F5EBC7F83E">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB4A64F3-9026-443B-A0F5-49B5AF1CEA56">
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F7C77E5-CD77-4EEB-B9A7-819B66A75D1A">
    <pav:createdOn>2014-06-23 12:13:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7F7C77E5-CD77-4EEB-B9A7-819B66A75D1A</domeo:uuid>
    <ao:exact>Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ions, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F7C77E5-CD77-4EEB-B9A7-819B66A75D1A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:57:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk. </ao:prefix>
    <ao:suffix>. In women with breast cancer who are at high risk of developing a second breast cancer, treatment with about 5 years of tamoxifen reduced the annual incidence rate of a second breast cancer by approximately 50%.</ao:suffix>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A3DC838-7F98-44F7-B8BE-DB357CB2F83F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A96B774-6D63-4E84-809D-9CE326458668">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9220F5FF-F228-443C-9B4F-81F507AD0EC9">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>how many annotations?
difference between CYP2C9*2, and CYP2C9*3
carriers?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3563965-B210-42C0-9FF0-A3486F2240E1">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A48D75D-6190-4AB9-A732-DF3E0BEA8B37">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5827AA3-0BA3-44C0-BB2B-FE3580D7D73A">
    <domeo:uuid>B5827AA3-0BA3-44C0-BB2B-FE3580D7D73A</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-08-10 21:27:44 -0400</pav:createdOn>
    <ao:exact>Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of CAMPTOSAR treatment.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B5827AA3-0BA3-44C0-BB2B-FE3580D7D73A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBDEA3B2-55BF-4555-AD74-97D937C09549">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE4EC397-CC34-40DB-8366-77AACB51DEAB">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D37E1623-1515-4F6A-93D4-F3BD2BBC1DE1">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34B06981-AD0F-44A1-BD68-B4BA60859FD8">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FC340C7-3054-4024-A6D3-03D1C8C19F0C">
    <rdfs:label>Imatinib</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D032294E-CED1-410A-B8D7-381F84967E05">
    <poc:MedicalCondition>Breast Cancer
Age
Women</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE0888E1-BFCD-4735-8AE9-6C63EC65E364">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DA1AA1D-8283-4F46-95E0-D8738048383A">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBE98CAE-777E-44FA-8D7A-DB8EA4CA18D2">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68EEF7BA-9B61-4E29-A647-F27CEF6A0C9A">
    <ao:body rdf:resource="urn:linkedspls:uuid:54F8A6A5-EE5C-45DF-8A38-5132EF95B1F7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25076BD9-8093-4214-AC5F-0AE3A20130ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:03C23462-7E7D-41B1-AB32-63E89902C1EA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:38F68FBD-9699-4F58-B96F-81A6CCDEEF14"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C973E9B-5F63-41AB-8FD5-CF3A9FCA95DF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:03859D1A-F06B-4FA2-89CC-7E8D927EF68A"/>
    <pav:lastSavedOn>2014-06-23 12:09:26 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:BCEB5C61-180F-4DF9-A0EA-3FED8818AF99</pav:previousVersion>
    <pav:createdOn>2014-06-23 12:08:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45793E8C-5643-4C7C-B634-31B99FE71E94</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FEDB1F4-881B-4964-9159-142BCBEB395D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDA25E4F-5AD6-49AC-BFDC-FB737EF18E43">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81499F1E-9A6F-4CB7-A780-7D37A0EDE924">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>UGT1A1*28, UGT1A1 7/7, UGT1A1 6/6</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:698DED5B-0966-49DB-A5A0-88E02DBD1E0B">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E140DE6F-DDD3-4D85-86B9-5A73C2EEB94C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3700E10D-A41A-41CE-B5E9-C568C9A79178">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF284ED1-7B3E-4A3C-9CD1-8AEBB065A0F7">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7F17286-FB75-48FC-A688-AC8AAFDD0EB6">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Not change from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D26531AA-6B60-402A-8811-F888FC608BDC">
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AB6F307-87A7-4718-8807-327A89AC39E4">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:304BC021-E734-4EB0-BB31-8EC9289EEA29">
    <rdfs:label>Ph Chromosome</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://www.fakeuri.com</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF5B1B86-3B07-49E5-BF20-8CD6F84E663D">
    <rdfs:label>Change in route of administration</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-in-route-of-admin</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to add change the route of administration for the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A1E5365-AE78-48D0-A03B-32D33C4DB5DA">
    <ncit:Alleles>UGT1A1*28,UGT1A1 6/6,UGT1A1 6/7</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7023AA5-1DAE-4A0B-A217-69F8C8A1DFCC">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1CD2473-CFAA-4FF5-809A-08E5500CC025">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D93C557-7BA6-4DCF-B075-71C884D5D59F">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4FDB6D9-6003-4748-9F44-DAD96C90C75E">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A1BD9E2-2528-4021-8820-53386159F540">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DBC567B-06FC-4E32-AF97-1F12BA46DF14">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A0FAD9F-FD88-4599-80E1-3EF4E8822F08">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E7CA85B-4A8F-4CBE-8231-92F268786E9F">
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB72EBD3-8FAF-4CC6-AD82-74EE55FB1C67">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB72EBD3-8FAF-4CC6-AD82-74EE55FB1C67"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BB72EBD3-8FAF-4CC6-AD82-74EE55FB1C67</domeo:uuid>
    <ao:suffix> (see Tables 14)</ao:suffix>
    <ao:exact>When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele [see Dosage and Administration (2.1 and 2.2) and Warnings and Precautions (5.3)]. However, the precise dose reduction in this patient population is not known, and subsequent dose modifications should be considered based on individual patient tolerance to treatment</ao:exact>
    <pav:createdOn>2014-08-10 21:33:41 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94ADE34C-D689-4935-81C9-D5C7435911A2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal, breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2EF7F52-F1D9-47EF-A074-4194D2550A74">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9E08AB9-C391-4B7F-9FD1-9B221053D7E3">
    <ncit:Alleles>homo for F508del,CFTR </ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CD56515-EE89-4871-8989-575D25CD76D6">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8C502EF-8F14-4202-BFF9-463CE5DA169B">
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A18AC49-4F82-4AE2-B58C-9068D4CE2A8B">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:777356F6-9617-4A7E-BF6D-EC58735B2B5D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>unknown and positive = separate annotation
maybe no need for second sentence?
</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B12F04A-876C-40C2-BD49-80D7A1174AE8">
    <poc:Comment>can this statement stand alone?\n</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54F8A6A5-EE5C-45DF-8A38-5132EF95B1F7">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F5428A8-04B1-4598-99C2-43DB74E0B647">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>premenopausal 
oophorectomy 
ovarian irradiation
irradiation
metastatic breast cancer
breast cancer
cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7B7C87B-58AA-4F8C-81B4-DF55D622D0B8">
    <poc:MedicalCondition>Depression</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A373252B-CF9E-478E-8ECD-B451ED7FC5DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-09 20:20:41 -0400</pav:createdOn>
    <ao:exact>The level of phenytoin should be carefully monitored in patients taking XELODA and phenytoin dose may need to be reduced [see Dosage and Administration (2.2)]. Postmarketing reports indicate that some patients receiving XELODA and phenytoin had toxicity associated with elevated phenytoin levels. Formal drug-drug interaction studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme by capecitabine and/or its metabolites.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A373252B-CF9E-478E-8ECD-B451ED7FC5DB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A373252B-CF9E-478E-8ECD-B451ED7FC5DB</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7028FEDD-7155-405A-A774-8FCE4035A758">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>CML and Ph+ ALL</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7613632E-D5CD-486C-AA25-3777E3521ADD">
    <pav:previousVersion>urn:domeoserver:annotationset:4034F2D7-4D06-41F3-8D94-F04B5C5F898E</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:FDF7BD4E-553F-4F43-9E6A-1BDDB1AE305A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304642b062014642cf8be10000"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:78BB6A54-2C48-44AF-BC4F-5130336B0B4A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BFBC3AC-D8B5-415E-AB79-C58932414E1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:DEC9D18C-6445-44EC-B75C-63977BD61F35</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-06-01 20:37:20 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N683bb8d746494ef49081f889d72ec125"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A25A28C-E3A8-4E68-AE36-EFD658F4D76F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9A48574-7F84-4D1C-B3B1-C7F5BD271B81"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:605401F9-CEC0-4386-9F96-10216E94DB09"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C243EC9-2225-4772-9FAC-3D93C17E4CAF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E008FAD-D62D-493D-800E-B4DB7F181625"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629ce3c370001</pav:createdBy>
    <pav:createdOn>2014-06-01 18:23:14 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:166E1275-A150-4DA6-9690-B18CDA86FA54"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1407863-3005-4220-AB14-446C3EC7B195"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:35FB2E8E-AD51-4F49-993D-2C68F0FDE171"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629ce3c370001"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F96E312-FA4B-452F-9AD1-A471C984DE2C">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D45E220-3807-489B-B2BF-EC91BDA967CC">
    <ncit:Alleles>CYP3A4, CYP2A6, CYP2C19</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2BC2D8C9-E400-4714-A9F8-522CD445CB23">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1302EB76-E1D9-4A85-B199-2A527967E8C1">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89CAE038-F224-48D4-8F50-A0118B7242FF">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:075A7CA2-6401-4610-A335-F1E2AE43B9E0">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6281053-9FBB-4089-87CE-BFFA4C1A86FA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>B6281053-9FBB-4089-87CE-BFFA4C1A86FA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6281053-9FBB-4089-87CE-BFFA4C1A86FA"/>
    <pav:createdOn>2014-08-10 22:44:57 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> (</ao:suffix>
    <ao:exact>CYP3A inhibitors: Reduce KALYDECO dose to 150 mg twice a week when co-administered with strong CYP3A inhibitors (e.g., ketoconazole). Reduce KALYDECO dose to 150 mg once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Avoid food containing grapefruit or Seville oranges.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECAC2FA7-FAA7-485D-A99C-271BB5D62013">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>F5</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3542</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48C45D74-0A72-4857-8E30-ED8E550324AF">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EBA90CA-E217-4D55-B7B6-63C5FD55B5E0">
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C49849A-1D00-4AB4-B40F-F15EBE87D0B0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D87F1F2-02FF-47FB-BE00-E115E4BE49D6">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43639865-D15D-44CD-B29C-C1DE608FAC81">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>does the ER positive/ ER poor influence the test result?\nI struggled to use this statement.  It seems important to include because it directly correlates with the biomarker levels in the patients being used in the study, but should it stand alone from the rest of the study?\n</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44B83470-7A63-4402-A977-48C1847BDF4D">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8447B718-31ED-46AB-8E85-2072C71545DE">
    <ao:exact>The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver. In vitro studies indicate that irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 10% of the North American population is homozygous for the UGT1A1*28 allele (also referred to as UGT1A1 7/7 genotype). In a prospective study, in which irinotecan was administered as a single-agent (350 mg/m2) on a once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had a higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>8447B718-31ED-46AB-8E85-2072C71545DE</domeo:uuid>
    <pav:createdOn>2014-08-10 22:19:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8447B718-31ED-46AB-8E85-2072C71545DE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9">
    <domeo:uuid></domeo:uuid>
    <ao:exact>Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <pav:createdOn>2014-06-01 18:44:56 -0400</pav:createdOn>
    <ao:suffix> (1.1)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FBD8FD1-24C2-473F-A864-16F7B7D1D3F9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3CB14A4C-8812-4724-A0EC-5FBD71584EFB">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43931AD4-BEEA-4BC8-AA5D-CADF429BA9A1">
    <domeo:uuid>43931AD4-BEEA-4BC8-AA5D-CADF429BA9A1</domeo:uuid>
    <pav:createdOn>2014-06-23 11:56:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:43931AD4-BEEA-4BC8-AA5D-CADF429BA9A1"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.6,7</ao:exact>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03859D1A-F06B-4FA2-89CC-7E8D927EF68A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97894498-771C-4274-B512-B487D71522F6">
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:294D1B8B-6C69-42C3-B2E0-9A4F3FD352CC">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F756ED20-FA04-4BDF-BC09-9FBC85BDC887">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDEE7E7A-C23A-4DCD-BED6-BB6915FC115A">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Change schedule</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:944D45CF-CD4D-4D1F-9774-4B161B17A3D0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Irinotecan</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A10D537E-04E7-41F2-9631-AEDCE1B74585">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Genotype</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4E2AC9B-4244-4885-9DC2-2B361565B06E">
    <pav:createdOn>2014-08-09 20:44:28 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4E2AC9B-4244-4885-9DC2-2B361565B06E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:suffix> There is no experience with Gleevec treatment in children under 1 year of age.</ao:suffix>
    <domeo:uuid>D4E2AC9B-4244-4885-9DC2-2B361565B06E</domeo:uuid>
    <ao:exact>Alternatively, in children with CML the daily dose may be split into two - one portion dosed in the morning and one portion in the evening.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B3931F7-E70A-466D-8C09-934673F99DDA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38F3F61C-AEB5-4D37-A01A-754F6DB5B6D2">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06A3420D-A05F-4067-82E2-17543B600AA4">
    <ncit:Alleles>CYP2C9*1,CYP2C9*2,CYP2C9*3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15B7AF82-B5F2-4FF0-9558-6A06D36E22B5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:182124B1-5996-466F-858E-FC532C12BD72">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C93E6EF6-A816-4813-938D-C1FE6702DC55">
    <ncit:Alleles>UGT1A1*28</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F95282A-14FE-42FB-87B5-900AA0BBA0FA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB356CAD-C0F8-4B4C-9C25-8CC9A8604A8E">
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CC422AD-3150-4062-B2B7-734941FBC7FA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>pd impact implication or clear cut?
no specific test recomendation however indicates there is one
estrogen and progesterone are in many products (does this warrent cocomitatnt med concern?

biomarker positive and unknown + 2 annotations?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2BF3473-D005-42A0-BEE4-6A0A276400D1">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78D36F0A-2543-4ACB-B09D-3C3A84A6F928">
    <ncit:Alleles>UGT1A1*28, UGT1A1 6/6, UGT1A1 6/7</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:793B8BBA-0114-4E55-961B-4B4093C70479">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nddd1e6b254364ab1a863f18da95610c7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B06CC265-F8E0-4C28-9939-880EF88A5101">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43682-4) PHARMACOKINETICS</poc:productLabelSection>
    <sio:SIO_000111>(43682-4) PHARMACOKINETICS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07689067-83B2-4A59-B4F7-83DFCFA0ED5D">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>positive or unknown = 2 annotations</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DD28267-65FB-4736-98AA-42F22B2AF105">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32A43506-436E-45E7-8BEF-AC69213D3AA9">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A81D2EF-029A-415B-B597-6299C70A58C8">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7044D8AD-2E9A-4764-8005-C08DC9ACB3C5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not change from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:241AC904-E593-4A48-9E32-7846142BF6D0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3A0C91F-5436-4E90-9D20-F2E2F3F67F14">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E645C77C-8BC4-47FE-B696-8385699C98BC">
    <pav:createdOn>2014-08-09 20:20:27 -0400</pav:createdOn>
    <ao:exact>CYP2C9 substrates: Care should be exercised when XELODA is coadministered with CYP2C9 substrates.</ao:exact>
    <ao:suffix> (</ao:suffix>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E645C77C-8BC4-47FE-B696-8385699C98BC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CAPECITABINE-a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E645C77C-8BC4-47FE-B696-8385699C98BC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D8090C8-06F6-4036-A295-0A093E356489">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08B0B51B-D5DC-40CD-B081-FA75E1BD984D">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0271F8DE-EF25-43F8-A34E-E34F28B73616">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B716172-F68E-4EFB-9A90-7067FE508F97">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77163E48-FDB2-4C0A-A127-B74C2095634E">
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AFD6F26E-7280-4ECC-9675-EB5879DA5B53">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5059D4A7-9D0A-44E8-A4A0-7CCEDE4D1D57">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>should we specify wild type vs others?
</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9A32269-12E8-4F88-B586-093F86654667">
    <ao:exact>Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene</ao:exact>
    <pav:createdOn>2014-08-10 22:32:33 -0400</pav:createdOn>
    <ao:suffix>. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9A32269-12E8-4F88-B586-093F86654667"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>E9A32269-12E8-4F88-B586-093F86654667</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62F162C4-135E-4C80-90D5-5AE8570228F2">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdfs:label>BRAF</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33049BC0-4665-43EC-8226-84723CC7AC54">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:372181D7-40ED-4B57-BA0B-D2ED888000E1">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D14ACD4-0847-4931-973E-9006DB7D24A1">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <pav:createdOn>2014-08-10 23:20:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D14ACD4-0847-4931-973E-9006DB7D24A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2D14ACD4-0847-4931-973E-9006DB7D24A1</domeo:uuid>
    <ao:exact>When KALYDECO is being co-administered with strong CYP3A inhibitors (e.g., ketoconazole), the dose should be reduced to 150 mg twice a week. The dose of KALYDECO should be reduced to 150 mg once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Food containing grapefruit or Seville oranges should be avoided</ao:exact>
    <ao:suffix> [</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D281CDBD-9057-40C6-9414-F16357D3042C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03C23462-7E7D-41B1-AB32-63E89902C1EA">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93B927C1-2F20-4DBC-B29B-D1455CC09205">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B4C100B-79CD-44F8-9EBE-37292F3907B3">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:523071B4-7A9B-4843-94CE-574131C7DAB0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A448D700-3F1E-4D64-870C-505840A1EC4E">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44">
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-02 11:33:05 -0400</pav:createdOn>
    <ao:prefix>In the Hubay study, tamoxifen was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, tamoxifen was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil (F). </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CEF2E37B-C0A4-4F4B-A2A8-38BEC4B8DD44"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F9F0CCA-B6E8-41D6-84C8-186912D7E20B">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000004801</dailymed:pharmgxBiomarker>
    <rdfs:label>BRAF</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B513A5-D56D-4DF6-A372-20CB0B78A444">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>tumor</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C534AB6B-3248-491F-A5F1-F1E88408C5A3">
    <rdfs:label>ALK</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:427</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0672652F-D2D6-4850-B292-41777DDD93A4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5A65BEB-DCCF-48F2-BE58-B211F9B5FBB1">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA0A4DC4-408C-4EEC-A396-79968EDA93F6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDE35E41-6B9A-4949-9334-3BA2C5FC0448">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79497636-6A03-45A6-A318-BD8D5DB418C9">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CFTR G551D, CFTR G1244E, CFTR G1349D, CFTR G178R, CFTR G551S, CFTR S1251N, CFTR S1255P, CFTR S549N, and CFTR S549R</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75F69FE6-25C0-4682-B792-5AD11062986C">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5266AAA4-C8B8-4FA4-9CB0-2815856888CB">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE20F363-A208-47A4-89DD-9BA37E9DFC28">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Xeloda and Warfarin? separate write ups?
Depends on drug in question the following annotation does. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B15AACC-C1D4-45B5-96D6-FBB023BC5F3B">
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF47BD25-ABBC-45C5-816F-2E7FBC1E9E01">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59B04B6B-FA6C-4EFE-9F81-8CDE5C500E0B">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:613A1FEB-89E1-4409-B873-D77B591CA651">
    <rdfs:label>Capecitabine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9838E62C-2417-4CE2-A1B4-B03A0F6B2C84">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06FA4BBD-EBB3-42A6-8835-4B46EC74B8FA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <rdfs:label>Imatinib</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82B4B70A-A7ED-4A04-9BB4-206EF37C2508">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F212693A-E0F3-4F5D-81E2-7422222513C4">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51D8AD88-84BD-499D-89B1-5A13D094E89B">
    <poc:Comment>BRCA1 and BRCA2 are not found in the FDA table. Are they relevant? Would this statement be annotated if they were? ESR1 was used as a place holder for the required section.  </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99474912-AAF4-4456-AA66-26B7DD743B6A">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:928318F4-75B6-4942-841F-EEAC3724CEC6">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5077EC81-E9B2-4F29-AE51-2A51E75DCBE2">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D093E80C-8C3F-4367-AB75-18154005898A">
    <poc:MedicalCondition>Cystic Fibrosis </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9AAB24E-347C-44AC-9337-70D4C8D31CA1">
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:402EEAA2-F9CC-46AF-9550-E45E115692FE">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B901F682-13D1-4291-9125-3CD610827426">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:854159CB-9EDA-4075-8EA9-8582AC113366">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34090-1) CLINICAL PHARMACOLOGY</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34090-1) CLINICAL PHARMACOLOGY</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:451D05CA-4BB1-46B3-81DE-57753077DCC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>G20210A</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE3F7756-C92E-42ED-9AA4-26948D671E54">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5654E5A-29EC-44FE-85CA-DDC4C8E58B7D">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC8F5C14-C49E-4393-A15D-899E694863B8">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F737D4DC-5A36-440B-91D8-76894236E232">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#no-change-necessary</poc:DrugSelectionRecommendation>
    <rdfs:label>Not change necessary</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27C8597A-EDFF-421B-8E00-B56F268B206D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA854708-62EF-4C38-A8D4-DCF90367088F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE43A038-2DA8-4D99-981D-214332A7F7C0">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED7BAF5C-D6A1-4037-914B-DC48038794EF">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E118AF70-C2CB-42BF-9C66-805D9273A823">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>medication guide = patient medication information?\n</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF266C1-FA4F-4B1F-AEE8-A51CF72207CB">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAEA2C0B-9BFC-4566-8723-27638A73064A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77FB8661-A2DD-439B-B8DD-146100034BF9">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Imatinib</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F532E4-DE6A-4195-8A66-D15780958299">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <pav:createdOn>2014-08-10 23:44:54 -0400</pav:createdOn>
    <ao:prefix>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>31F532E4-DE6A-4195-8A66-D15780958299</domeo:uuid>
    <ao:exact>The overall safety profile of KALYDECO is based on pooled data from three placebo-controlled clinical trials conducted in 353 patients with CF who had a G551D mutation in the CFTR gene (Trials 1 and 2) or were homozygous for the F508del mutation (Trial 3). In addition, an 8-week crossover design trial (Trial 4) involving 39 patients with a G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene was conducted. Patients treated with KALYDECO in these trials were between the ages of 6 and 57 years.\nOf the 353 patients included in the pooled analyses of patients with CF who had either a G551D mutation or were homozygous for the F508del mutation in the CFTR gene, 50% of patients were female and 97% were Caucasian; 221 received KALYDECO and 132 received placebo from 16 to 48 weeks.\nThe proportion of patients who prematurely discontinued study drug due to adverse reactions was 2% for KALYDECO-treated patients and 5% for placebo-treated patients. Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.\nThe most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\nThe incidence of adverse reactions below is based upon two double-blind, placebo-controlled, 48-week clinical trials (Trials 1 and 2) in a total of 213 patients with CF ages 6 to 53 who have a G551D mutation in the CFTR gene and who were treated with KALYDECO 150 mg orally or placebo twice daily. Table 1 shows adverse reactions occurring in 8% of KALYDECO-treated patients with CF who have a G551D mutation in the CFTR gene that also occurred at a higher rate than in the placebo-treated patients in the two double-blind, placebo-controlled trials.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31F532E4-DE6A-4195-8A66-D15780958299"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF07AC73-5059-43CA-A262-B59652BEDC03">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CFTR G551D,CFTR G1244E, CFTR G1349D, CFTR G178R, CFTR G551S, CFTR S1251N, CFTR S1255P, S549N, and CFTR S549R</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867A2668-77BC-4F6A-987C-114E9D9549C9">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2643A08-C95E-48C6-930F-8CE9B9775384">
    <poc:MedicalCondition>ovariectomy
adrenalectomy
hypophysectomy
breast cancer
cancer
progesterone therapy?
estrogen therapy?
tumor growth
tumor progression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69D70A19-BD83-4C1B-BE23-D5B62C7C1389">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF99415E-699B-49E4-B42D-8C12C707766C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:523C86B8-DDA8-4C60-87C5-0E5E7B37AB61">
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4BA538D-61A7-4EAD-8570-A3A806489044">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>3A4 should be added to HGNC Gene Symbol Selection
Rifampin
letrozole 
tamoxifen </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D017E663-B46B-4580-B8C0-29ACBDCAB4AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D017E663-B46B-4580-B8C0-29ACBDCAB4AE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-23 12:06:15 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D017E663-B46B-4580-B8C0-29ACBDCAB4AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D42F9F66-D37B-4507-91FA-136AEA8DA642">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F33AF78F-8D13-42EE-B8C1-8C92CD33E60F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6656052D-E3F6-4660-8905-DFB8B98C0CC7">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>effecaiciy and do not start?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED21B315-38D0-4925-8381-807711159BD6">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CC1A70D-952A-454E-BAF0-4254B50EEE9F">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB06DF4A-6F26-409D-BB3A-8A01E4B34C0D">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>do not change drug rec and dose rec</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3DEDAB0-2203-467F-A767-BF51E2926DD7">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BC4D324-CC64-42F6-BE5A-6538E9028251">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07F88819-D6E2-461A-A044-5E3CEC9E1E63">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F912A186-EFE8-4683-829C-7D3591BC246E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AA0A022-FEC0-431B-83B2-D6933B368C60">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E495D799-FBD4-414C-B469-19EB5A801B2C">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:651715CC-218D-471B-B935-8C20D7F158A1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Imatinib</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00619</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A76CAD7-6AFA-4C1E-AFDD-B56F1FA2AD22">
    <poc:Comment>ESR1 vs ER_Receptor? Why does the FDA table refer to PGR?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8AE2753-37D4-4732-9BDC-A8BCBDC66097">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E14686CF-A588-49E9-83B3-334780748182">
    <ao:context rdf:resource="urn:domeoclient:uuid:7B2E9778-C8C5-442E-9DD2-1DB882A461AB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0E96817-EA06-4EBD-BB41-5F0C2D631D81</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:79497636-6A03-45A6-A318-BD8D5DB418C9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-10 23:06:05 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-08-10 23:06:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:4E267E9E-2E0F-46DF-BAE4-058F1EEE8F21</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:372181D7-40ED-4B57-BA0B-D2ED888000E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6444E3DF-9538-405D-9B09-616E34C4B756"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AB5FB6FD-C2E7-4202-814F-6F2C244D0BB3</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D58D76C-8E3C-4BA5-BAF3-61389559D329"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E442401A-CA63-48A5-88AB-988579C6AE5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:273F41C8-6FEB-478E-9B7B-89E3D99894F0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:801E4361-583C-4097-9F47-7910FDF70718">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B6A567A-02D0-4DF0-93D0-7EE0108B7492">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04D23969-1D1F-4A9A-B1FB-3952D8158677">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E4CFCEC-52F1-4DC3-8C7D-958E0CBB0930">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CFTR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC41527C-085A-4940-B990-08A2D0350C2C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5738AE20-15FF-4DBA-87E3-67FAB9159316">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>UGT1A1*28 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4ECB73F8-17F3-4625-9FEA-64F11014F951">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77373F3B-8EA0-4F35-A16C-9D6271129C95">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F778B550-CF93-48BA-AA2B-C31FCD5B5C0C">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*2,CYP2C9*3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC4553F8-50E9-48FE-8430-0D301DE2E7DE">
    <pav:createdOn>2014-08-10 22:07:18 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Dexamethasone, a moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan.</ao:exact>
    <domeo:uuid>EC4553F8-50E9-48FE-8430-0D301DE2E7DE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC4553F8-50E9-48FE-8430-0D301DE2E7DE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14A4B8C7-A2F8-4432-9D84-03A047BA880A">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal women
metastatic breast cancer
locally advanced breast cancer
breast cancer
cancer
antiestrogen therapy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF4B710F-A32F-47E2-BECB-106A837F1F66">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D9E4522-945F-4A0F-9E1E-DA98FE8B3BDC">
    <ncit:Alleles>UGT1A1*28</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95883503-619E-47C5-A2AA-69C742D7C90B">
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5A01BA3-C965-4226-BB21-CD71F0AF3F8A">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18131683-7CC8-445D-8167-63ACA1A3B3D2">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Change monitoring strategy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49C91135-7B0C-49C9-B2B9-940C06C1D40B">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Cystic Fibrosis, abdominal pain, increased hepatic enzymes,  hypoglycemia, headache, upper respiratory tract infection, nasal congestion, nausea, rash , rhinitis, dizziness, arthralgia, and bacteria in sputum</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB28026C-C47A-45ED-AA26-E514F6865F6C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8D60E72-87CF-4F20-8B7F-3DE216B184DD"/>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix> Among these patients, 54% had node-positive disease and 46% had node-negative disease.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-01 20:26:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F90BB48-9E97-4846-A924-6BDE2BA21548">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Phenotype?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C819792D-415B-45BE-A528-AFC18D3037EA">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFD6D71F-C2BF-4A93-AA87-5ED9808A94CD">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6C8E47C-538E-43BD-8DBF-B72C7C5D6099">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Irinotecan</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17C174F1-29A3-409B-A824-DEB39FFC2604">
    <rdfs:label>Change monitoring strategy</rdfs:label>
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:724D3B35-67C5-43A4-BC96-46E359B92EE8">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8CE207E-13B7-4302-ADFF-08E5EA02E0FC">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:939532D8-0588-46A2-9E45-D593E1510B49">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FEDB1F4-881B-4964-9159-142BCBEB395D">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC57C085-7B4C-44C1-A2D0-5A7911093AC6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:364E48E3-9581-476A-B552-7EF20E3B5123">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal women
metastatic breast cancer
advanced breast cancer
breast cancer
cancer
antiestrogen therapy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2783EC2F-6C89-4C26-B46B-31A86D1360CA">
    <ao:exact>A laboratory test is available to determine the UGT1A1 status of patients. Testing can detect the UGT1A1 6/6, 6/7 and 7/7 genotypes.</ao:exact>
    <pav:createdOn>2014-08-10 22:00:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2783EC2F-6C89-4C26-B46B-31A86D1360CA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2783EC2F-6C89-4C26-B46B-31A86D1360CA"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EC426D3-528C-4BEB-81E7-B910EBA3E1B5">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B64B9D8-3BE7-46A5-99E8-51142C33754A">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:971C0313-9F4E-49B3-8319-EE5DC4F29891">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7CD345E-09A1-47B2-B5D4-517A0F033D8C">
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N42cbc0d5672e4338842f20f82c88c906">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8A08744-2AEE-46C6-95C7-7CD50737E7F4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:445CC80C-C238-4D86-9748-F26C4AD69228">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60AB858A-177D-4161-91FD-6FB672AE1AC5">
    <poc:MedicalCondition>grade 4 neutropenia, neutropenia </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA352C73-C1EA-4D7D-AE35-0CFDE97E6F6F">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB280D71-62FB-40FB-94CD-233483856A93">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7762E8FF-2F66-49F9-8F33-6361BE15F2B6">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CF02485-5245-4315-841B-AF795A211207">
    <poc:MedicalCondition>bleeding risk, carriers</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBF04D85-16FE-4392-BAA3-393C676C0B40">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F2E59F3-E967-44CA-8CFB-87772F1A6B4C">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#no-change-necessary</poc:DrugSelectionRecommendation>
    <rdfs:label>Not change necessary</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3962F73F-9B04-454E-BFA8-92F762C8334D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A529F9B-BB09-4226-B859-5957E0612554">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:391B05C5-B412-4155-80AD-9318BA217C9B">
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DD80216-E6DB-48BD-A9C1-D37C6D156E4F">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34073-7) DRUG INTERACTIONS</poc:productLabelSection>
    <sio:SIO_000111>(34073-7) DRUG INTERACTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9631DAFD-657D-4B15-B45C-6749370AB9DC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76EA7D30-E3C4-4197-A7B4-293995F38E7C">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to add a concomitant medication.</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#addition-of-medication</poc:DrugSelectionRecommendation>
    <rdfs:label>Addition of medication</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA0E4629-4676-4414-9CCE-D47355EFE0B2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Where is CYP3A4?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F54608AB-77EF-415E-A3DD-3DD07F40A174">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C94E7B6D-85F6-4A00-8BE8-CCEEA58A9D9C">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF63EA96-E9D9-4793-9240-BC5E99A6F4AF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-10 22:05:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>St. John's wort: Exposure to the active metabolite SN-38 is reduced in patients receiving concomitant St. John's wort. St. John's wort should be discontinued at least 2 weeks prior to the first cycle of irinotecan, and St. John's wort is contraindicated during irinotecan therapy.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>FF63EA96-E9D9-4793-9240-BC5E99A6F4AF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF63EA96-E9D9-4793-9240-BC5E99A6F4AF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60B4A42A-5A0B-4AAB-B5E9-D49C6FDBA62B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADC2C0BA-8531-4C8E-9016-F3E0BD15B5E3">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26ED1574-E13A-4959-9E4F-45BE4BDA351E">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAF55A68-F83C-4EA3-ACCE-A7D22C0D74A8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85062DD4-AC27-4671-801E-7592AC985BD2">
    <rdfs:label>ALK</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:427</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DBDA217-1594-4A26-BB47-582F603B9509">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA55D176-702F-49C5-B3F4-628AE90E0E1C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C39973DF-3681-4FBE-ACBC-79FEF9643453">
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16175971-B5AE-48AB-9C1F-13487FB63F5F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4C62951-37E6-4AFA-87DE-9E72DB44B268">
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60B2FC2A-0FCD-47E1-8AF6-036903D2D8FE">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1056089-0FB5-44D2-A976-B96EE2910380">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:556DBB2A-7A01-4225-9193-57FAA5081013">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91383B95-AE29-4D4E-82B3-2565E0F7C5AD">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CFTR F508del </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7AE4498-0791-430D-971B-593DFED47C18">
    <pav:createdOn>2014-08-09 20:08:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-08-09 20:21:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:716AA449-886E-4EEB-BA11-F9A08EB6C6C7"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16038AB1-F8FD-4AA1-B5DB-C48F4CC01BA0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A461FB23-AD27-4338-B215-B0EEB975D2FD"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4883DD92-91BF-458F-88A5-E2857AE33002"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4607D130-54A4-475F-8D06-53BC41F21B1B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E69D5D39-08C2-4F6A-82D2-9BB1F2BAE7B2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFF8F6B3-CBEA-41C1-8B89-E750F37D5BF0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:402D6FD3-64B6-4499-92F6-7C3BC95DD990"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304642b062014642cf8be10000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBD0203C-5085-46C8-9967-6925BBD433DA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5A40A436-DB97-4F9D-A2CE-71234ECF455A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D14C1107-3ED0-4351-923C-D114C4559F07</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FBA0754-1C09-46E9-8403-905ED4826F03">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EF6BFC4-564D-45AE-A0FD-E209B90914B7">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410">
    <ao:suffix> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estr</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:43:33 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFA36CF5-82DD-42C0-8AEC-980D7F409410"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B38E1606-AC23-4903-9AB5-50032A302E19">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D3D660C2-955B-4037-A95B-5711916747A8">
    <ncit:Alleles>UGT1A1*28,UGT1A1 7/7 </ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A4B363B-C27F-4AB6-B71E-79BCC511008A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. I</ao:prefix>
    <pav:createdOn>2014-06-23 12:11:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A4B363B-C27F-4AB6-B71E-79BCC511008A"/>
    <ao:exact>f the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (seeCLINICAL PHARMACOLOGYandPRECAUTIONS).\nThe patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:exact>
    <domeo:uuid>2A4B363B-C27F-4AB6-B71E-79BCC511008A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7925A8BE-4401-4E13-A60C-0CFB0EFB7480">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:211BDD97-B2B1-4815-8C1F-EB8664060C81">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>re not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8369C922-5F94-4382-A0B9-A7423698A59D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8369C922-5F94-4382-A0B9-A7423698A59D</domeo:uuid>
    <ao:exact>There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-02 11:44:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EDBAB4E-9BCC-40E2-84C7-354A385E17B9">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5C48B4D-07D6-4422-8681-560601367419">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>clotting factor synthesis</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38F68FBD-9699-4F58-B96F-81A6CCDEEF14">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:046E02CC-B43C-460B-B30D-89DC3C4C51E2">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Amitriptyline</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00321</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52659CB2-2836-4827-AA04-68D75C4A4B31">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16038AB1-F8FD-4AA1-B5DB-C48F4CC01BA0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E3BC098-863B-4FD1-9E5F-F4C244D690CD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd298722e097b4d27ba310aeeee12c500">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E59B98C-D1FE-41D7-81D3-C3A9E7617BAD">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E19C86C-AF8F-4049-B770-4A8BB73E1C87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C42C9A0-2255-41A3-B346-EC49AA4FB231">
    <rdfs:label>Irinotecan</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E54A8F3F-19BB-4FB2-8D79-2CEC0CD3C261">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DD7DD05-2925-4F7F-B8C0-A4A75F188272">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C4D4FB4-3EB6-430F-BC08-637D2E095D79">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>neutropenia, grade 4 neutropenia </poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA5CB1FD-D1F7-4527-A5EC-8F6AD26EDF25">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A26E190-386D-487C-9204-1A9FF093B3BF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:416FC75E-6F07-42CC-A084-7EFDF0B22B6A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA82B2B8-D75E-48D2-805D-7373ECD081EA">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12F85D8C-0C64-4074-AD70-0023DF39FE0C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Irinotecan</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6207BDE-B892-441F-BE0A-0D7E3B0CC6B7">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A18250EA-6D04-4F8A-9913-544C0BDC8A33">
    <rdfs:label>CFTR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CEA8726-35F7-4552-BB24-EE3069597FDB">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CFTR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12153C41-67BB-4F0C-86FF-7E4F110181F5">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3146B9AA-68A2-4E19-91D9-D0AC98F6AC7C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:563D84AA-9BEE-4BA8-8D08-3A4F5F473A1F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>pk pd impact implication or specific?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59FA88B5-7EA5-4974-9C1C-29E4CE65FE56">
    <poc:Comment>Drug in question is Xeloda, not phenytoin. SHould this be two write ups? Or should this just be under Xeloda?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C5D336C-1591-47DB-9267-FBB2AE135DC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F752A03-E83D-4F05-BFA5-733989528DC5">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6D4A6F1-109F-462F-9CA4-78E8572F04D5">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F2E15C6-E95F-4A74-9F00-48CF06B103E4">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AA8627E-CA88-4386-8040-4A006B86F19F">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E22833FF-9C8C-4AAF-BF61-7A1BAC88B9EE">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BA002F2-35EE-4CE2-BCB7-FE83BF8FF7A5">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B77509C-B4A9-48D8-8281-20CE902E914A">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77FA206B-E97B-4DB2-95C8-2CAEE18D73ED">
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98E92217-DD29-4B26-ACE9-A724F91D498F">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CC4F394-A7AE-487F-8E39-26BA985A73C4">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7C6F945-F6AB-415D-815F-D36B9BEA98A3">
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA139D1F-5943-42B5-B46F-936534FF180D">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>BRCA1 BRCA2</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43D32FD1-DA85-469D-A0E5-5FBD43C0EF54">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0F83D6C-DD82-4333-BFF3-DE92D85685DC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21A69B54-0A85-4DDC-8458-D6A971254E87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F354912-5F3D-49DA-AAB4-6F25C6574A88">
    <ao:exact>The recommended dose of Gleevec for children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600 mg).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-09 20:47:17 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3F354912-5F3D-49DA-AAB4-6F25C6574A88"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3F354912-5F3D-49DA-AAB4-6F25C6574A88</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMATINIB-211ef2da-2868-4a77-8055-1cb2cd78e24b.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32C7D92F-8B7C-4FC1-BE72-43A4987726AC">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C895D7E-E97D-4CC6-9FC9-7EF9E64CAB4B">
    <poc:Comment>same or different due to addition of 5-FU/LV?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF079F40-0025-456F-8288-81DF3604F1DA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A0FC3DC-9928-45C0-BB39-67AF50042771">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFE6B916-956A-471C-A188-5B6E1DE9D592">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F1A881E-327B-4A8F-842E-98D7A69CA8E4">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F75844DB-E53D-4A7E-8248-E2D1AE992D03">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9B7673C-D5C1-460F-BBC9-3E98308394E0">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15CAD71A-E73D-41C4-A612-FD85495EA125">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6894BC08-84DE-4272-B1B2-1CCDD5AF8ADD">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFA9A1B1-F6CA-4A27-A169-261051BF3E8A">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:057E63DB-B25B-4E76-9FB2-B358F7686200">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:715FBAF4-B02C-4176-9F1B-0A9DD25FB455">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1483C104-1035-4F90-B6A1-E546F30356A4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0483221-F475-4081-ADBF-98A1997B6D25">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:402D6FD3-64B6-4499-92F6-7C3BC95DD990">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52A069C8-DE95-46AC-AD2C-ED7E1E47462D">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD496EA6-ABF1-4F0C-A3F2-C1D79B30F4AF">
    <rdfs:label>CFTR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AE58537-F6FF-4692-BBCE-D614E552418A">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34084-4 ADVERSE REACTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34084-4 ADVERSE REACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCFB7B91-25DB-40CF-A05D-7A83778BB16D">
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A026AEA3-3F53-4917-90B1-26247C59DE43">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BE4D17A-C226-4AFB-A8B7-25943C052F09">
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF5088B6-388D-4934-9857-FD769E87D8A1">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>UGT1A1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F71F1BDE-257C-47CF-B351-3DA8C736B140">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6ACCDAF7-66DD-4016-AADA-48DE1CB7DFA8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31EE354A-10AC-4F7D-86B9-07D649455403">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78BC8B81-3B71-454A-B26D-897291620340">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D79ADB35-0606-4365-AF87-AA29A89CD77C">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>UGT1A1*28, UGT1A1 6/7,UGT1A1 6/6 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DA58976-B060-4F74-BC58-B197894534CD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Change schedule</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83BEA37D-2B27-4864-B526-C93110E8DB8F">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01101</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Capecitabine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E442401A-CA63-48A5-88AB-988579C6AE5D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4101E819-5264-4B71-9EB8-F0A70B83A01B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:189E8CA1-5263-4DF9-B8BB-A0969A5A2277">
    <ncit:Alleles>CYP2C9*5,CYP2C9*6,CYP2C9*9,CYP2C9*11</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07BDCF78-FF4E-4E7B-B35D-B720E7D377B6">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33882B0A-6CEE-4FA1-A9E0-996AD46C70AF">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7691AE7C-224B-4543-B17C-D604B3F149F0">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9949262E-8BE7-4F5E-AD93-41E04F76FE41">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:939C0307-55CE-4736-AA11-38175F4EE10A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22783C7-ABFC-4DA3-8A47-F388EB9CA645">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:351BC453-B1E8-429D-9160-EB7AC9985DFA">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62CF9D0F-F138-4528-B2C3-F4C7D3D6F71A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B7C227F-856D-4CF2-A4C0-EED0DEC4B506">
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:836A37A7-4D0B-4AFA-8D09-94C3EA62FCE1">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8ED8D02-7F93-41B5-908B-D5A8A907DF30">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF6E49B3-BB09-40AD-9D47-A996FC2ED92D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-10 22:43:42 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF6E49B3-BB09-40AD-9D47-A996FC2ED92D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>FF6E49B3-BB09-40AD-9D47-A996FC2ED92D</domeo:uuid>
    <ao:exact>The most common adverse drug reactions to KALYDECO (occurring in 8% of patients with CF who have a G551D mutation in the CFTR gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:888B1342-C453-47DA-B417-3463BE7491AD">
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBB3AC8A-6B1E-443C-9E5A-F8E3DBAD2600">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32DCFD4A-6714-434C-AA86-D67DC3A89BA4">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>BRCA? \nESR1 used as a place holder\npatient medication information?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80C6E754-D72B-4024-8D61-FEF86F5C6A3E">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:744677B2-4EB0-44F1-B7CB-E8D281EB0F80">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdfs:label>CFTR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC1949CD-5C5D-4C24-B2E1-52904E49993D">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A301196-021F-4EE3-B07C-470C0C57EBDC">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F0C0FB9-DF19-4D6E-949F-6ADC00A8977C">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4EB1751-EA99-44EF-AF37-8F62006DC59D">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90C7CDC4-7785-42F1-95CA-9FC7A3CD3BFC">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>this is just a shitty SPL... we need to use the brand ones's. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32E1E9EA-32B8-460F-B557-2CA8E3B4CC01">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F1D72A7-73E0-4C9B-935C-5EDCCA2982ED">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>pk and pd impact implicated
more than  one annotation possible
no clinical condition related effect
dose indicate concomitatn med concern of above CYPs
metabolite activity unknown
clinical trial information?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E5DA6FF-D900-4436-B714-1C6B44F671AA">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>cyp3a4 </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:973A257C-A669-4CFF-AA07-27EA5C59A05E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis </poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA8988F3-1346-4B78-A914-D18381CEF56A">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA75E90E-DD48-4D34-BF92-E73CE9762328">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Ancestry</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:781BBA63-F58B-4E56-AD8A-0062F37377E4">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1913406-D5F7-4C32-A307-A55268FB07FA">
    <poc:Comment>double check HGNC and biomarker (need to add)</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF3691C6-184F-4B0B-A35B-2A7D10DECD85">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in distribution of the drug.</dct:description>
    <rdfs:label>Distribution Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#distribution-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:339670C1-0475-4E89-9865-932C014CDE44">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>ovariectomy
adrenalectomy
hypophysectomy
breast cancer
cancer
progesterone therapy?
estrogen therapy?
tumor growth
tumor progression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5D5A83A-B881-497C-989F-283E7BB1F539">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>neutropenia</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CC9E564-0104-4F47-826B-D8A1DB07DEAF">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:619014FA-87B2-4D3C-9270-E7257598EEC8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>not relevant?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B78860AC-3C6B-422E-94F7-069AA1226270">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Ancestry </poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55CB7EF8-A6B6-4D3F-9A7F-DCF6A7E08FE4">
    <poc:Comment>Highlights section</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFDB86E6-8AD1-4119-89A0-128288422892">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Ancestry for Asian, Cuacastian etc</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N92b2bbd591074e989703ab27234f0de5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FCC9F3C-187A-4D10-B907-FACC9E668E85">
    <poc:Comment>inhibition of CYP P450?
enzyme genetic? 
I am confused as to why this is not highlighted by anyone else
</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FC2FDC3-15E8-4CB3-8CA4-01B7647070B0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>I split this and the following annotation up to make the distinction between the different test results</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4FF148F-DA8E-460A-9416-12EABD3C0787">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, postmenopausal,</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4D7DAE8-56DD-4A33-85A4-992C189CFF7F">
    <ncit:Alleles>CYP2C9*2,CYP2C9*1,CYP2C9*3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44301F97-7088-46C4-BB32-27D413FE3A60">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>G20210A?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59D463C5-ED0D-4FAD-8454-93F2D804878B">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>endogenous estrogen
aldosterone
thyroid hormones
thyroid 
adrenal corticosteroid synthesis
hormone replacement therapy?</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
</rdf:RDF>
